DDPD-ID,Drug-Name,SMILES,Molecular Weight (g/mol),C-Max Value (ng/ml),C-Max Unit,C-Max Raw Value,C-Max Annotation,C-Max (nM)
DDPD00007,Leuprolide,CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1,1209.3983,108.3,ng/ml,4.6-212,"intravenous injection, IV;",89.55
DDPD00035,Desmopressin,NC(=O)CC[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O,1069.22,0.004,ng/ml,4.00±3.85,"inhalation, IH;",0.00
DDPD00035,Desmopressin,NC(=O)CC[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O,1069.22,0.00911,ng/ml,9.11±6.90,"inhalation, IH;",0.01
DDPD00080,Daptomycin,CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)C2=CC=CC=C2N)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)[C@H](C)CC(O)=O,1620.693,99000.0,ng/ml,99±12,"intravenous infusion, IV in drop;",61084.98
DDPD00091,Cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,1202.635,1101.0,ng/ml,1101±570,"PO, oral; Drug form; renal transplant;",915.49
DDPD00091,Cyclosporine,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,1202.635,1333.0,ng/ml,1333±469,"PO, oral; Drug form; renal transplant;",1108.40
DDPD00104,Octreotide,[H][C@]1(NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@H](CO)[C@@H](C)O)NC(=O)[C@H](N)CC1=CC=CC=C1)[C@@H](C)O,1019.25,2.5,ng/ml,2.5,"Capsule, PO, Oral; acromegaly;",2.45
DDPD00104,Octreotide,[H][C@]1(NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@H](CO)[C@@H](C)O)NC(=O)[C@H](N)CC1=CC=CC=C1)[C@@H](C)O,1019.25,5.3,ng/ml,5.3,"Capsule, PO, Oral; acromegaly;",5.20
DDPD00106,Abarelix,CC(C)C[C@H](NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC1=CN=CC=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=C(C=CC=C2)C=C1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,1416.09,43.4,ng/ml,43.4,"IM,intramuscular injection;",30.65
DDPD00136,Calcitriol,C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C,416.6365,0.06,ng/ml,60.0±4.4,Oral single dose;,0.14
DDPD00136,Calcitriol,C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C,416.6365,0.09,ng/ml,~90,"PO, oral;",0.22
DDPD00136,Calcitriol,C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C,416.6365,0.105,ng/ml,~105,"Intraperitoneal, IP;",0.25
DDPD00136,Calcitriol,C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C,416.6365,0.46,ng/ml,~460,"intravenous injection, IV;",1.10
DDPD00175,Pravastatin,[H][C@]12[C@H](C[C@H](O)C=C1C=C[C@H](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC(O)=O)OC(=O)[C@@H](C)CC,424.5277,42.5,ng/ml,30-55,"PO, oral;",100.11
DDPD00175,Pravastatin,[H][C@]12[C@H](C[C@H](O)C=C1C=C[C@H](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC(O)=O)OC(=O)[C@@H](C)CC,424.5277,33.0,ng/ml,28-38,Oral single dose;,77.73
DDPD00177,Valsartan,CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O,435.5188,1600.0,ng/ml,1.6±0.6,"Male, men; adults; normal,healthy;",3673.78
DDPD00178,Ramipril,[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC,416.5106,43.3,ng/ml,43.3±10.2,"PO, oral;",103.96
DDPD00178,Ramipril,[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC,416.5106,24.1,ng/ml,24.1±5.6,"PO, oral; Active metabolite;",57.86
DDPD00181,Baclofen,NCC(CC(O)=O)C1=CC=C(Cl)C=C1,213.661,160.0,ng/ml,160±49,Oral single dose;,748.85
DDPD00186,Lorazepam,OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2,321.158,48.0,ng/ml,48.0,"IM,intramuscular injection;",149.46
DDPD00186,Lorazepam,OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2,321.158,28.0,ng/ml,~28,"PO, oral; adults; normal,healthy;",87.18
DDPD00186,Lorazepam,OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2,321.158,30.0,ng/ml,~30,"IM,intramuscular injection; adults; normal,healthy;",93.41
DDPD00186,Lorazepam,OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2,321.158,75.0,ng/ml,~75,"intravenous injection, IV; adults; normal,healthy;",233.53
DDPD00188,Bortezomib,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O,384.237,57.0,ng/ml,57.0,"intravenous injection, IV;",148.35
DDPD00188,Bortezomib,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O,384.237,112.0,ng/ml,112.0,"intravenous injection, IV;",291.49
DDPD00188,Bortezomib,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O,384.237,86.5,ng/ml,67-106,"intravenous injection, IV;",225.12
DDPD00188,Bortezomib,CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O,384.237,104.5,ng/ml,89-120,"intravenous injection, IV;",271.97
DDPD00190,Carbidopa,C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O,226.2292,85.0,ng/ml,0.085,"PO, oral;",375.73
DDPD00190,Carbidopa,C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O,226.2292,165.0,ng/ml,165±77,"PO, oral; Drug form; adults; normal,healthy;",729.35
DDPD00190,Carbidopa,C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O,226.2292,81.0,ng/ml,81±28,"PO, oral; Drug form; adults; normal,healthy;",358.04
DDPD00193,Tramadol,COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C,263.3752,300.0,ng/ml,300.0,Oral single dose;,1139.06
DDPD00193,Tramadol,COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C,263.3752,348.0,ng/ml,348.0,Oral multiple dose;,1321.31
DDPD00193,Tramadol,COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C,263.3752,166.0,ng/ml,166.0,"IM,intramuscular injection;",630.28
DDPD00193,Tramadol,COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C,263.3752,294.0,ng/ml,294.0,Rectal Administration;,1116.28
DDPD00193,Tramadol,COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C,263.3752,592.0,ng/ml,592±178,"Tablet, PO, oral; immediate release formulation;",2247.74
DDPD00193,Tramadol,COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C,263.3752,110.0,ng/ml,110±32,"Tablet, PO, oral; Active metabolite; immediate release formulation;",417.66
DDPD00196,Fluconazole,OC(CN1C=NC=N1)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1,306.2708,10600.0,ng/ml,10.6±0.4,"PO, oral; adults; normal,healthy;",34609.89
DDPD00198,Oseltamivir,CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1,312.4045,65.0,ng/ml,65.0,"Capsule, PO, Oral; food;",208.06
DDPD00198,Oseltamivir,CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1,312.4045,348.0,ng/ml,348.0,"Capsule, PO, Oral; food; Active metabolite;",1113.94
DDPD00199,Erythromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,733.9268,1.8,ng/ml,1.8,"PO, oral;",2.45
DDPD00199,Erythromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,733.9268,2200.0,ng/ml,0.9-3.5,"PO, oral; extended release formulation;",2997.57
DDPD00199,Erythromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,733.9268,950.0,ng/ml,0.5-1.4,"Tablet, PO, oral;",1294.41
DDPD00201,Caffeine,CN1C=NC2=C1C(=O)N(C)C(=O)N2C,194.1906,8000.0,ng/ml,6-10,"PO, oral;",41196.64
DDPD00203,Sildenafil,CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1,474.576,212.0,ng/ml,212±59,,446.71
DDPD00204,Dofetilide,CN(CCOC1=CC=C(NS(C)(=O)=O)C=C1)CCC1=CC=C(NS(C)(=O)=O)C=C1,441.565,2.3,ng/ml,2.3±1.1,"Oral single dose; Male, men; adults; normal,healthy;",5.21
DDPD00207,Azithromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,748.9845,400.0,ng/ml,0.4,"PO, oral; adults; patients;",534.06
DDPD00210,Adapalene,COC1=C(C=C(C=C1)C1=CC2=C(C=C1)C=C(C=C2)C(O)=O)C12CC3CC(CC(C3)C1)C2,412.5201,0.553,ng/ml,0.553±0.466,skin/dermal;,1.34
DDPD00213,Pantoprazole,COC1=C(OC)C(CS(=O)C2=NC3=C(N2)C=C(OC(F)F)C=C3)=NC=C1,383.37,2.5,ng/ml,~2.5,Oral single dose; food;,6.52
DDPD00215,Citalopram,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1,324.3919,50.0,ng/ml,50±9,Oral single dose; Drug form;,154.13
DDPD00215,Citalopram,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1,324.3919,21.0,ng/ml,21±4,Oral single dose; Drug form;,64.74
DDPD00218,Moxifloxacin,[H][C@]12CN(C[C@@]1([H])NCCC2)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1OC)C(O)=O,401.4314,2500.0,ng/ml,2.5±1.3,"Oral single dose; Male, men; adults; normal,healthy;",6227.71
DDPD00220,Nelfinavir,[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C,567.782,3200.0,ng/ml,3.2±1.2,"adults; AIDS,HIV;",5635.97
DDPD00222,Glimepiride,CCC1=C(C)CN(C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O,490.62,359.0,ng/ml,359±98,Oral single dose;,731.73
DDPD00227,Lovastatin,[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC,404.5396,3.013,ng/ml,3.013,,7.45
DDPD00227,Lovastatin,[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC,404.5396,2.535,ng/ml,1.04-4.03,"PO, oral;",6.27
DDPD00227,Lovastatin,[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC,404.5396,41.0,ngEq/ml,41±6,"PO, oral; Active metabolite;",101.35
DDPD00227,Lovastatin,[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC,404.5396,50.0,ngEq/ml,50±8,"PO, oral; Active metabolite;",123.60
DDPD00231,Temazepam,CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1,300.74,824.0,ng/ml,666-982,,2739.91
DDPD00231,Temazepam,CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1,300.74,865.0,ng/ml,865.0,,2876.24
DDPD00238,Nevirapine,CC1=C2NC(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1,266.2979,2000.0,ng/ml,2±0.4,"PO, oral;",7510.39
DDPD00238,Nevirapine,CC1=C2NC(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1,266.2979,2000.0,ng/ml,2±0.4,"Oral single dose; adults; AIDS,HIV;",7510.39
DDPD00238,Nevirapine,CC1=C2NC(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1,266.2979,4500.0,ng/ml,4.5±1.9,"Oral multiple dose; adults; AIDS,HIV;",16898.37
DDPD00241,Butalbital,CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O,224.2563,2100.0,ng/ml,2.1,"PO, oral;",9364.29
DDPD00245,Benzatropine,[H][C@]12CC[C@]([H])(C[C@@]([H])(C1)OC(C1=CC=CC=C1)C1=CC=CC=C1)N2C,307.4293,2.5,ng/ml,2.5,"PO, oral;",8.13
DDPD00246,Ziprasidone,ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1,412.936,68.0,ng/ml,68±20,"PO, oral;",164.67
DDPD00246,Ziprasidone,ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1,412.936,156.0,ng/ml,156.0,,377.78
DDPD00250,Dapsone,NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1,248.301,1600.0,ng/ml,1.6±0.4,"Oral single dose; adults; normal,healthy;",6443.79
DDPD00250,Dapsone,NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1,248.301,3300.0,ng/ml,3.3,"Oral multiple dose; adults; normal,healthy;",13290.32
DDPD00252,Phenytoin,O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1,252.268,675.0,ng/ml,0-5(27%),"Capsule, PO, Oral;",2675.73
DDPD00252,Phenytoin,O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1,252.268,2250.0,ng/ml,5-10(30%),"Capsule, PO, Oral;",8919.09
DDPD00252,Phenytoin,O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1,252.268,4350.0,ng/ml,10-20(29%),"Capsule, PO, Oral;",17243.57
DDPD00252,Phenytoin,O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1,252.268,2500.0,ng/ml,20-30(10%),"Capsule, PO, Oral;",9910.10
DDPD00254,Doxycycline,[H][C@@]12[C@@H](C)C3=CC=CC(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O,444.4346,2600.0,ng/ml,2.6,Oral single dose;,5850.13
DDPD00254,Doxycycline,[H][C@@]12[C@@H](C)C3=CC=CC(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O,444.4346,1850.0,ng/ml,1.7-2,"PO, oral; adults;",4162.59
DDPD00254,Doxycycline,[H][C@@]12[C@@H](C)C3=CC=CC(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O,444.4346,2800.0,ng/ml,2.8,adults;,6300.14
DDPD00256,Lymecycline,[H][C@@]12C[C@@]3([H])C(C(=O)C4=C(O)C=CC=C4[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(=O)NCNCCCC[C@H](N)C(O)=O)=C(O)[C@H]2N(C)C,602.6328,2100.0,ng/ml,2.1,"PO, oral;",3484.71
DDPD00264,Metoprolol,COCCC1=CC=C(OCC(O)CNC(C)C)C=C1,267.3639,99.0,ng/ml,99±53,"PO, oral; extensive metabolizers, EM;",370.28
DDPD00264,Metoprolol,COCCC1=CC=C(OCC(O)CNC(C)C)C=C1,267.3639,262.0,ng/ml,262±29,"PO, oral; poor metabolizers, PM;",979.94
DDPD00268,Ropinirole,CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1,260.3746,7.4,ng/ml,7.4(2.4-13),"PO, oral; Parkinson;",28.42
DDPD00273,Topiramate,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,339.362,15215.0,ng/ml,1.73-28.7,"PO, oral;",44834.13
DDPD00273,Topiramate,[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2,339.362,5500.0,ng/ml,5.5±0.6,"PO, oral; adults; normal,healthy; epilepsy;",16206.88
DDPD00275,Olmesartan,CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O,446.5016,1160.0,ng/ml,0.22-2.1,"PO, oral;",2597.98
DDPD00277,Theophylline,CN1C2=C(NC=N2)C(=O)N(C)C1=O,180.164,7900.0,ng/ml,7.9±0.6,"PO, oral; Drug form; adults; normal,healthy;",43848.94
DDPD00277,Theophylline,CN1C2=C(NC=N2)C(=O)N(C)C1=O,180.164,15000.0,ng/ml,15±2.8,"PO, oral; Drug form; adults; normal,healthy;",83257.48
DDPD00277,Theophylline,CN1C2=C(NC=N2)C(=O)N(C)C1=O,180.164,14000.0,ng/ml,14±3.7,"PO, oral; Drug form; adults; normal,healthy;",77706.98
DDPD00279,Liothyronine,N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C=C2)C(I)=C1)C(O)=O,650.9735,34600.0,ng/ml,346.0,Oral multiple dose;,53151.17
DDPD00281,Lidocaine,CCN(CC)CC(=O)NC1=C(C)C=CC=C1C,234.3373,3500.0,ng/ml,2-5,,14935.74
DDPD00282,Pamidronic acid,NCCC(O)(P(O)(O)=O)P(O)(O)=O,235.0695,1920.0,ng/ml,1.92±1.08,"normal,healthy;",8167.80
DDPD00282,Pamidronic acid,NCCC(O)(P(O)(O)=O)P(O)(O)=O,235.0695,1860.0,ng/ml,1.86±0.50,mild renal function;,7912.55
DDPD00282,Pamidronic acid,NCCC(O)(P(O)(O)=O)P(O)(O)=O,235.0695,1840.0,ng/ml,1.84±0.58,moderate renal function;,7827.47
DDPD00282,Pamidronic acid,NCCC(O)(P(O)(O)=O)P(O)(O)=O,235.0695,1930.0,ng/ml,1.93±0.53,severe renal function;,8210.34
DDPD00285,Venlafaxine,COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1,277.4018,167.0,ng/ml,167±55,"PO, oral; immediate release formulation; adults; normal,healthy;",602.01
DDPD00285,Venlafaxine,COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1,277.4018,397.0,ng/ml,397±81,"PO, oral; Active metabolite; immediate release formulation; adults; normal,healthy;",1431.14
DDPD00286,Conjugated estrogens,CC12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)[O-].[Na+],N.A.,2.6,ng/ml,2.6,Oral multiple dose;,
DDPD00287,Travoprost,CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(=C1)C(F)(F)F,500.5477,0.025,ng/ml,<25,ophthalmic administration;,0.05
DDPD00289,Atomoxetine,CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1,255.3547,350.0,ng/ml,350.0,"PO, oral;",1370.64
DDPD00289,Atomoxetine,CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1,255.3547,160.0,ng/ml,160.0,"PO, oral; extensive metabolizers, EM;",626.58
DDPD00289,Atomoxetine,CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1,255.3547,915.0,ng/ml,915.0,"PO, oral; poor metabolizers, PM;",3583.25
DDPD00295,Morphine,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O,285.3377,80.7505691,ng/ml,283.0,"PO, oral;",283.00
DDPD00295,Morphine,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O,285.3377,70.0,ng/ml,~70,"IM,intramuscular injection;",245.32
DDPD00295,Morphine,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O,285.3377,10.0,ng/ml,10.0,"PO, oral; immediate release formulation;",35.05
DDPD00295,Morphine,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O,285.3377,7.4,ng/ml,7.4,"PO, oral; Sustained Release formulation;",25.93
DDPD00295,Morphine,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O,285.3377,300.0,ng/ml,200-400,,1051.39
DDPD00296,Ropivacaine,CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C,274.4011,1100.0,ng/ml,1.1±0.2,,4008.73
DDPD00296,Ropivacaine,CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C,274.4011,2300.0,ng/ml,2.3±0.8,skin/dermal;,8381.89
DDPD00297,Bupivacaine,CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C,288.4277,800.0,ng/ml,0.8,epidural administration; adults; patients;,2773.66
DDPD00300,Tenofovir disoproxil,[H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C,519.448,330.0,ng/ml,0.33±0.12,"PO, oral;",635.29
DDPD00304,Desogestrel,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCCC=C3CC[C@@]21[H],310.473,2.0,ng/ml,2.0,"PO, oral;",6.44
DDPD00310,Chlorthalidone,NS(=O)(=O)C1=C(Cl)C=CC(=C1)C1(O)NC(=O)C2=CC=CC=C12,338.766,3700.0,ng/ml,3.7±0.9,"Male, men; adults; normal,healthy;",10921.99
DDPD00313,Valproic acid,CCCC(CCC)C(O)=O,144.2114,34000.0,ng/ml,34±8,"Capsule, PO, Oral; Drug form; Male, men; adults; normal,healthy;",235765.00
DDPD00315,Zolmitriptan,CN(C)CCC1=CNC2=CC=C(C[C@H]3COC(=O)N3)C=C12,287.3568,20.6,ng/ml,16-25.2,"Tablet, PO, oral;",71.69
DDPD00316,Acetaminophen,CC(=O)NC1=CC=C(O)C=C1,151.1626,20000.0,ng/ml,20,"PO, oral;",132307.86
DDPD00317,Gefitinib,COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1,446.902,341.0,ng/ml,341±208,"PO, oral; tumor;",763.03
DDPD00318,Codeine,[H][C@]12C=C[C@H](O)[C@@H]3OC4=C5C(C[C@H]1N(C)CC[C@@]235)=CC=C4OC,299.3642,149.0,ng/ml,149±60,"PO, oral; Male, men; adults; normal,healthy;",497.72
DDPD00318,Codeine,[H][C@]12C=C[C@H](O)[C@@H]3OC4=C5C(C[C@H]1N(C)CC[C@@]235)=CC=C4OC,299.3642,3.8,ng/ml,3.8±2.4,"PO, oral; Active metabolite; Male, men; adults; normal,healthy;",12.69
DDPD00321,Amitriptyline,CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12,277.4033,64.0,ng/ml,64±35,adults;,230.71
DDPD00327,Hydromorphone,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O,285.3377,0.0,null,~0,parenteral administration;,0.00
DDPD00327,Hydromorphone,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O,285.3377,11.8,ng/ml,11.8±2.6,"PO, oral; Male, men; normal,healthy;",41.35
DDPD00327,Hydromorphone,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O,285.3377,242.0,ng/ml,242.0,"intravenous injection, IV; Male, men; normal,healthy;",848.12
DDPD00328,Indomethacin,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O,357.788,1540.0,ng/ml,1.54±0.76,,4304.22
DDPD00328,Indomethacin,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O,357.788,2650.0,ng/ml,2.65±1.03,,7406.62
DDPD00328,Indomethacin,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O,357.788,4920.0,ng/ml,4.92±1.88,,13751.16
DDPD00328,Indomethacin,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O,357.788,2400.0,ng/ml,~2.4,Oral single dose; food;,6707.88
DDPD00330,Ethambutol,CC[C@@H](CO)NCCN[C@@H](CC)CO,204.3098,3500.0,ng/ml,2-5,,17130.85
DDPD00331,Metformin,CN(C)C(=N)NC(N)=N,129.1636,1600.0,ng/ml,1.6±0.2,"Tablet, PO, oral;",12387.39
DDPD00331,Metformin,CN(C)C(=N)NC(N)=N,129.1636,2050.0,ng/ml,1.0-3.1,"PO, oral;",15871.34
DDPD00333,Methadone,CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1,309.4452,689.5,ng/ml,124-1255,"PO, oral;",2228.18
DDPD00333,Methadone,CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1,309.4452,524.5,ng/ml,69-980,"PO, oral; patients;",1694.97
DDPD00333,Methadone,CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1,309.4452,500.0,ng/ml,450-550,"intravenous injection, IV; patients;",1615.79
DDPD00334,Olanzapine,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2,312.432,156.9,ng/ml,156.9,"PO, oral; food;",502.19
DDPD00334,Olanzapine,CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2,312.432,12.9,ng/ml,12.9±7.5,"Oral single dose; Male, men; normal,healthy;",41.29
DDPD00335,Atenolol,CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1,266.3361,280.0,ng/ml,0.28±0.09,Oral single dose;,1051.30
DDPD00339,Pyrazinamide,NC(=O)C1=NC=CN=C1,123.1127,35000.0,ng/ml,35(19-103),"PO, oral;",284292.36
DDPD00341,Cetirizine,OC(=O)COCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1,388.888,311.0,ng/ml,311.0,"Tablet, PO, oral; Capsule, PO, Oral; normal,healthy;",799.72
DDPD00341,Cetirizine,OC(=O)COCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1,388.888,313.0,ng/ml,313±45,"Oral single dose; normal,healthy;",804.86
DDPD00343,Diltiazem,COC1=CC=C(C=C1)[C@@H]1SC2=C(C=CC=C2)N(CCN(C)C)C(=O)[C@@H]1OC(C)=O,414.518,151.0,ng/ml,151±46,"Oral single dose; adults; normal,healthy;",364.28
DDPD00358,Mefloquine,OC(C1CCCCN1)C1=CC(=NC2=C1C=CC=C2C(F)(F)F)C(F)(F)F,378.3122,910.0,ng/ml,800-1020,Oral single dose;,2405.42
DDPD00358,Mefloquine,OC(C1CCCCN1)C1=CC(=NC2=C1C=CC=C2C(F)(F)F)C(F)(F)F,378.3122,420.0,ng/ml,420±141,Oral multiple dose;,1110.19
DDPD00361,Vinorelbine,[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC,778.947,114.0,ng/ml,114±43,,146.35
DDPD00361,Vinorelbine,[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC,778.947,1130.0,ng/ml,1130±636,,1450.68
DDPD00363,Clozapine,CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12,326.823,546.0,ng/ml,546±307,"Tablet, PO, oral; adults;",1670.63
DDPD00367,Levonorgestrel,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],312.4458,16.2,ng/ml,16.2,"PO, oral;",51.85
DDPD00367,Levonorgestrel,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],312.4458,10.5,ng/ml,10.5,"PO, oral; Obesity;",33.61
DDPD00369,Cidofovir,NC1=NC(=O)N(C[C@@H](CO)OCP(O)(O)=O)C=C1,279.187,19600.0,ng/ml,19.6±7.2,,70203.84
DDPD00370,Mirtazapine,CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1,265.3529,41.8,ng/ml,41.8±7.7,"PO, oral;",157.53
DDPD00373,Timolol,[H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1,316.42,1.14,ng/ml,1.14,ophthalmic administration;,3.60
DDPD00373,Timolol,[H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1,316.42,61.0,ng/ml,61±39,"PO, oral; extensive metabolizers, EM;",192.78
DDPD00373,Timolol,[H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1,316.42,114.0,ng/ml,114±21,"PO, oral; poor metabolizers, PM;",360.28
DDPD00381,Amlodipine,CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,408.876,18.1,ng/ml,18.1±7.1,"PO, oral; Male, men; adults;",44.27
DDPD00384,Triamterene,NC1=NC(N)=C2N=C(C(N)=NC2=N1)C1=CC=CC=C1,253.2626,46.4,ng/ml,46.4,"Oral single dose; Male, men; fasting;",183.21
DDPD00384,Triamterene,NC1=NC(N)=C2N=C(C(N)=NC2=N1)C1=CC=CC=C1,253.2626,26.4,ng/ml,26.4±17.7,"Oral single dose; fasting; young; normal,healthy;",104.24
DDPD00384,Triamterene,NC1=NC(N)=C2N=C(C(N)=NC2=N1)C1=CC=CC=C1,253.2626,779.0,ng/ml,779±310,"Oral single dose; Active metabolite; fasting; young; normal,healthy;",3075.86
DDPD00384,Triamterene,NC1=NC(N)=C2N=C(C(N)=NC2=N1)C1=CC=CC=C1,253.2626,84.0,ng/ml,84±91,Oral single dose; Elderly;,331.67
DDPD00384,Triamterene,NC1=NC(N)=C2N=C(C(N)=NC2=N1)C1=CC=CC=C1,253.2626,526.0,ng/ml,526±388,Oral single dose; Active metabolite; Elderly;,2076.90
DDPD00390,Digoxin,[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1,780.9385,1.32,ng/ml,1.32±0.18,combination drug use;,1.69
DDPD00390,Digoxin,[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1,780.9385,1.4,ng/ml,1.4±0.7,"PO, oral; heart failure;",1.79
DDPD00390,Digoxin,[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1,780.9385,3.7,ng/ml,3.7±1.0,"PO, oral; heart failure;",4.74
DDPD00394,Beclomethasone dipropionate,[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,521.042,0.088,ng/ml,88.0,"PO, oral;",0.17
DDPD00394,Beclomethasone dipropionate,[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,521.042,35.356,ng/ml,35356.0,"PO, oral; different study;",67.86
DDPD00394,Beclomethasone dipropionate,[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,521.042,1.419,ng/ml,1419.0,Active metabolite;,2.72
DDPD00394,Beclomethasone dipropionate,[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,521.042,2.633,ng/ml,2633.0,different study; Active metabolite;,5.05
DDPD00394,Beclomethasone dipropionate,[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,521.042,0.703,ng/ml,703.0,"PO, oral; different study; Active metabolite;",1.35
DDPD00394,Beclomethasone dipropionate,[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,521.042,0.31,ng/ml,310.0,"inhalation, IH; different study; Active metabolite;",0.59
DDPD00396,Progesterone,[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,314.4617,7.0,ng/ml,7.0,"IM,intramuscular injection;",22.26
DDPD00396,Progesterone,[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,314.4617,28.0,ng/ml,28.0,"IM,intramuscular injection;",89.04
DDPD00396,Progesterone,[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,314.4617,50.0,ng/ml,50.0,"IM,intramuscular injection;",159.00
DDPD00399,Zoledronic acid,OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O,272.0896,370.0,ng/ml,370±78.5,"intravenous injection, IV;",1359.85
DDPD00399,Zoledronic acid,OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O,272.0896,471.0,ng/ml,471±76.1,"intravenous injection, IV;",1731.05
DDPD00404,Alprazolam,CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12,308.765,17.0,ng/ml,12-22,Oral single dose;,55.06
DDPD00404,Alprazolam,CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12,308.765,21.0,ng/ml,21(15-32),"PO, oral; adults;",68.01
DDPD00412,Rosiglitazone,CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C1=CC=CC=N1,357.427,598.0,ng/ml,598±117,Oral single dose;,1673.07
DDPD00413,Pramipexole,CCCN[C@H]1CCC2=C(C1)SC(N)=N2,211.327,1.6,ng/ml,1.6±0.23,"PO, oral; Male, men; normal,healthy;",7.57
DDPD00413,Pramipexole,CCCN[C@H]1CCC2=C(C1)SC(N)=N2,211.327,2.1,ng/ml,2.1±0.25,"PO, oral;  Female, women; normal,healthy;",9.94
DDPD00417,Phenoxymethylpenicillin,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)COC1=CC=CC=C1)C(O)=O,350.39,450.0,ng/ml,200-700,"PO, oral;",1284.28
DDPD00417,Phenoxymethylpenicillin,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)COC1=CC=CC=C1)C(O)=O,350.39,4000.0,ng/ml,3-5,,11415.85
DDPD00421,Spironolactone,[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O,416.573,209.0,ng/ml,209.0,"PO, oral;",501.71
DDPD00421,Spironolactone,[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O,416.573,301.0,ng/ml,301.0,"PO, oral; food;",722.56
DDPD00421,Spironolactone,[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O,416.573,185.0,ng/ml,185±51,"PO, oral;",444.10
DDPD00421,Spironolactone,[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O,416.573,231.0,ng/ml,231±49,"PO, oral; Active metabolite;",554.52
DDPD00421,Spironolactone,[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O,416.573,571.0,ng/ml,571±74,"PO, oral; Active metabolite;",1370.71
DDPD00421,Spironolactone,[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O,416.573,202.0,ng/ml,202±54,"PO, oral; Active metabolite;",484.91
DDPD00422,Methylphenidate,COC(=O)C(C1CCCCN1)C1=CC=CC=C1,233.3062,10.5,ng/ml,6-15,Children; Drug form;,45.01
DDPD00422,Methylphenidate,COC(=O)C(C1CCCCN1)C1=CC=CC=C1,233.3062,7.8,ng/ml,7.8,"PO, oral; Children; Drug form;",33.43
DDPD00422,Methylphenidate,COC(=O)C(C1CCCCN1)C1=CC=CC=C1,233.3062,10.8,ng/ml,10.8,"PO, oral; adults; Drug form;",46.29
DDPD00422,Methylphenidate,COC(=O)C(C1CCCCN1)C1=CC=CC=C1,233.3062,18.0,ng/ml,18±4.3,Oral single dose; Raceme D;,77.15
DDPD00422,Methylphenidate,COC(=O)C(C1CCCCN1)C1=CC=CC=C1,233.3062,3.0,ng/ml,3.0±0.9,Oral single dose; Raceme L;,12.86
DDPD00423,Methocarbamol,COC1=C(OCC(O)COC(N)=O)C=CC=C1,241.2405,21300.0,ng/ml,21.3,"normal,healthy;",88293.63
DDPD00423,Methocarbamol,COC1=C(OCC(O)COC(N)=O)C=CC=C1,241.2405,28700.0,ng/ml,28.7,,118968.42
DDPD00425,Zolpidem,CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1,307.3895,59.0,ng/ml,59.0,,191.94
DDPD00425,Zolpidem,CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1,307.3895,121.0,ng/ml,121.0,,393.64
DDPD00425,Zolpidem,CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1,307.3895,107.5,ng/ml,76-139,Oral single dose; adults; young;,349.72
DDPD00431,Lindane,Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl,290.83,28.0,ng/ml,28.0,skin/dermal;,96.28
DDPD00437,Allopurinol,OC1=NC=NC2=C1C=NN2,136.1115,3000.0,ng/ml,3.0,"PO, oral;",22040.75
DDPD00437,Allopurinol,OC1=NC=NC2=C1C=NN2,136.1115,1400.0,ng/ml,1.4±0.5,Oral single dose;,10285.68
DDPD00437,Allopurinol,OC1=NC=NC2=C1C=NN2,136.1115,6400.0,ng/ml,6.4±0.8,Oral single dose; Active metabolite;,47020.27
DDPD00438,Ceftazidime,[O-]C(=O)C1=C(CS[C@]2([H])[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C3=CSC(N)=N3)C(=O)N12)C[N+]1=CC=CC=C1,546.576,34000.0,ng/ml,29-39,"IM,intramuscular injection; adults; normal,healthy;",62205.44
DDPD00438,Ceftazidime,[O-]C(=O)C1=C(CS[C@]2([H])[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C3=CSC(N)=N3)C(=O)N12)C[N+]1=CC=CC=C1,546.576,132500.0,ng/ml,119-146,"intravenous injection, IV; adults; normal,healthy;",242418.25
DDPD00440,Trimethoprim,COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC,290.3177,1000.0,ng/ml,1.0,Oral single dose;,3444.50
DDPD00440,Trimethoprim,COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC,290.3177,2000.0,ng/ml,2.0,Oral single dose;,6889.00
DDPD00440,Trimethoprim,COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC,290.3177,1200.0,ng/ml,1.2,"Oral single dose; adults; normal,healthy;",4133.40
DDPD00441,Gemcitabine,NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F,263.1981,7080028.89,ng/ml,26.9±9,"intravenous infusion, IV in drop;",26900000.00
DDPD00448,Lansoprazole,CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1,369.361,248.0,ng/ml,248±140,"Oral single dose; Male, men; normal,healthy;",671.43
DDPD00454,Meperidine,CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1,247.3327,700.0,ng/ml,~0.7,"PO, oral;",2830.20
DDPD00454,Meperidine,CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1,247.3327,670.0,ng/ml,0.67,"intravenous injection, IV;",2708.90
DDPD00455,Loratadine,CCOC(=O)N1CCC(CC1)=C1C2=C(CCC3=C1N=CC=C3)C=C(Cl)C=C2,382.883,2.56,ng/ml,2.56,"PO, oral; immediate release formulation;",6.69
DDPD00455,Loratadine,CCOC(=O)N1CCC(CC1)=C1C2=C(CCC3=C1N=CC=C3)C=C(Cl)C=C2,382.883,3.72,ng/ml,3.72,,9.72
DDPD00455,Loratadine,CCOC(=O)N1CCC(CC1)=C1C2=C(CCC3=C1N=CC=C3)C=C(Cl)C=C2,382.883,3.72,ng/ml,3.72,immediate release formulation; Derivative;,9.72
DDPD00455,Loratadine,CCOC(=O)N1CCC(CC1)=C1C2=C(CCC3=C1N=CC=C3)C=C(Cl)C=C2,382.883,3.66,ng/ml,3.66,Derivative;,9.56
DDPD00455,Loratadine,CCOC(=O)N1CCC(CC1)=C1C2=C(CCC3=C1N=CC=C3)C=C(Cl)C=C2,382.883,3.4,ng/ml,3.4±3.4,"PO, oral; adults; normal,healthy;",8.88
DDPD00455,Loratadine,CCOC(=O)N1CCC(CC1)=C1C2=C(CCC3=C1N=CC=C3)C=C(Cl)C=C2,382.883,4.1,ng/ml,4.1±2.6,"PO, oral; Active metabolite; adults; normal,healthy;",10.71
DDPD00455,Loratadine,CCOC(=O)N1CCC(CC1)=C1C2=C(CCC3=C1N=CC=C3)C=C(Cl)C=C2,382.883,4.0,ng/ml,4.0±2.1,"PO, oral; Active metabolite; Drug form; adults; normal,healthy;",10.45
DDPD00455,Loratadine,CCOC(=O)N1CCC(CC1)=C1C2=C(CCC3=C1N=CC=C3)C=C(Cl)C=C2,382.883,2.0,ng/ml,2.0±0.6,"PO, oral; Active metabolite; Drug form; adults; normal,healthy;",5.22
DDPD00457,Prazosin,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1=CC=CO1,383.4011,36.0,ng/ml,36±17,Oral single dose; hypertension;,93.90
DDPD00458,Imipramine,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12,280.4073,200.0,ng/ml,200±137,"PO, oral;",713.25
DDPD00465,Ketorolac,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,255.2686,2600.0,ng/ml,2.2-3.0,"IM,intramuscular injection; adults; normal,healthy;",10185.35
DDPD00465,Ketorolac,OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1,255.2686,850.0,ng/ml,0.8-0.9,"PO, oral; adults; normal,healthy;",3329.83
DDPD00468,Quinine,[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12,324.4168,11000.0,ng/ml,11±2,"intravenous injection, IV; adults; malaria;",33907.00
DDPD00468,Quinine,[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12,324.4168,8350.0,ng/ml,7.3-9.4,"PO, oral; adults; malaria;",25738.49
DDPD00468,Quinine,[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12,324.4168,9050.0,ng/ml,8.7-9.4,"intravenous injection, IV; Children; malaria;",27896.21
DDPD00468,Quinine,[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12,324.4168,7300.0,ng/ml,7.3±1.1,"PO, oral; Children; malaria;",22501.92
DDPD00470,Dronabinol,[H][C@@]12C=C(C)CC[C@@]1([H])C(C)(C)OC1=C2C(O)=CC(CCCCC)=C1,314.4617,1.32,ng/ml,1.32,Oral single dose;,4.20
DDPD00471,Montelukast,OC(=O)CC1(CC1)CS[C@H](CCC1=CC=CC=C1C(O)(C)C)C1=CC=CC(\C=C\C2=NC3=C(C=CC(Cl)=C3)C=C2)=C1,586.183,542.0,ng/ml,542±173,Oral single dose;,924.63
DDPD00472,Fluoxetine,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1,309.3261,11.754,ng/ml,11.754,,38.00
DDPD00472,Fluoxetine,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1,309.3261,365.5,ng/ml,200-531,"PO, oral;",1181.60
DDPD00472,Fluoxetine,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1,309.3261,284.0,ng/ml,103-465,"PO, oral;",918.12
DDPD00477,Chlorpromazine,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=C(Cl)C=C2,318.864,87.5,ng/ml,25-150,"PO, oral; adults; patients;",274.41
DDPD00479,Amikacin,NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O,585.6025,21000.0,ng/ml,17-25,"normal,healthy; adults;",35860.50
DDPD00479,Amikacin,NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O,585.6025,38000.0,ng/ml,38.0,"intravenous injection, IV;",64890.43
DDPD00479,Amikacin,NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O,585.6025,26000.0,ng/ml,26±4,"intravenous infusion, IV in drop; RD, renal impairment, Renal disease，including uremia;",44398.72
DDPD00481,Raloxifene,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2,473.583,0.5,ng/ml,0.5,Oral single dose; postmenopausal women;,1.06
DDPD00481,Raloxifene,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2,473.583,1.36,ng/ml,1.36,Oral multiple dose; postmenopausal women;,2.87
DDPD00481,Raloxifene,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2,473.583,0.64,ng/ml,0.64,Oral single dose; postmenopausal women;,1.35
DDPD00481,Raloxifene,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2,473.583,1.7408,ng/ml,1.7408,Oral multiple dose; postmenopausal women;,3.68
DDPD00481,Raloxifene,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2,473.583,0.5,ng/ml,0.5±0.3,"PO, oral;",1.06
DDPD00482,Celecoxib,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F,381.372,705.0,ng/ml,705.0,,1848.59
DDPD00482,Celecoxib,CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F,381.372,705000.0,ng/ml,705±268,"Oral single dose; normal,healthy;",1848588.78
DDPD00484,Brimonidine,BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12,292.135,0.046,ng/ml,46±62,skin/dermal;,0.16
DDPD00485,Dicloxacillin,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl)C(O)=O,470.326,69000.0,ng/ml,47-91,"PO, oral; fasting; adults; normal,healthy;",146706.75
DDPD00486,Nabilone,[H][C@@]12CC(=O)CC[C@@]1([H])C(C)(C)OC1=CC(=CC(O)=C21)C(C)(C)CCCCCC,372.5408,2.0,ng/ml,~2,"PO, oral;",5.37
DDPD00489,Sotalol,CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1,272.364,6.25,null,6.25±2.19,"PO, oral; food;",22.95
DDPD00490,Buspirone,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1,385.5031,3.5,ng/ml,1-6,Oral single dose;,9.08
DDPD00490,Buspirone,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)C1=NC=CC=N1,385.5031,1.66,ng/ml,1.66±0.21,"Oral single dose; Male, men; adults; normal,healthy;",4.31
DDPD00494,Entacapone,CCN(CC)C(=O)C(=C\C1=CC(=C(O)C(O)=C1)[N+]([O-])=O)\C#N,305.286,4300.0,ng/ml,4.3±2.0,"PO, oral; Male, men; normal,healthy;",14085.15
DDPD00495,Zidovudine,CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O,267.2413,2600.0,ng/ml,2.6,"PO, oral;",9729.04
DDPD00495,Zidovudine,CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O,267.2413,1600.0,ng/ml,1.6,"intravenous injection, IV;",5987.10
DDPD00497,Oxycodone,COC1=C2O[C@H]3C(=O)CC[C@@]4(O)[C@H]5CC(C=C1)=C2[C@@]34CCN5C,315.3636,11.5,ng/ml,11.5,"PO, oral; patients;",36.47
DDPD00497,Oxycodone,COC1=C2O[C@H]3C(=O)CC[C@@]4(O)[C@H]5CC(C=C1)=C2[C@@]34CCN5C,315.3636,15.1,ng/ml,15.1±4.7,"PO, oral; extended release formulation;",47.88
DDPD00497,Oxycodone,COC1=C2O[C@H]3C(=O)CC[C@@]4(O)[C@H]5CC(C=C1)=C2[C@@]34CCN5C,315.3636,15.5,ng/ml,15.5±4.5,"PO, oral; immediate release formulation;",49.15
DDPD00499,Flutamide,CC(C)C(=O)NC1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F,276.2118,110.0,ng/ml,0.11±0.21,"PO, oral; Elderly;",398.25
DDPD00499,Flutamide,CC(C)C(=O)NC1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F,276.2118,1600.0,ng/ml,1.6±0.59,"PO, oral; Active metabolite; Elderly;",5792.66
DDPD00501,Cimetidine,CN\C(NCCSCC1=C(C)NC=N1)=N\C#N,252.339,2500.0,ng/ml,2-3,"Oral single dose; fasting; adults; normal,healthy;",9907.31
DDPD00502,Haloperidol,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1,375.864,22.0,ng/ml,22±18,"IM,intramuscular injection;",58.53
DDPD00502,Haloperidol,OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1,375.864,9.2,ng/ml,9.2±4.4,Oral single dose;,24.48
DDPD00503,Ritonavir,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,720.944,11000.0,ng/ml,11±4,"PO, oral;",15257.77
DDPD00512,Vancomycin,CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(N)[C@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2,1449.254,48500.0,ng/ml,18.5(15-25),"intravenous infusion, IV in drop;",33465.49
DDPD00512,Vancomycin,CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(N)[C@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2,1449.254,48500.0,ng/ml,18.5(15-25),"intravenous infusion, IV in drop; staphylococcal infections; streptococcal infections;",33465.49
DDPD00514,Dextromethorphan,[H][C@]12CCCC[C@]11CCN(C)[C@H]2CC2=C1C=C(OC)C=C2,271.404,2.9,ng/ml,2.9,"PO, oral;",10.69
DDPD00514,Dextromethorphan,[H][C@]12CCCC[C@]11CCN(C)[C@H]2CC2=C1C=C(OC)C=C2,271.404,5.2,ng/ml,5.2±1.8,"PO, oral; poor metabolizers, PM;",19.16
DDPD00514,Dextromethorphan,[H][C@]12CCCC[C@]11CCN(C)[C@H]2CC2=C1C=C(OC)C=C2,271.404,33.0,ng/ml,33±8.2,"PO, oral; extensive metabolizers, EM;",121.59
DDPD00514,Dextromethorphan,[H][C@]12CCCC[C@]11CCN(C)[C@H]2CC2=C1C=C(OC)C=C2,271.404,879.0,ng/ml,879±60,"PO, oral; Drug form; poor metabolizers, PM;",3238.71
DDPD00515,Cisplatin,[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H],300.05,3400.0,ng/ml,3.4±1.1,ovarian cancer;,11331.44
DDPD00515,Cisplatin,[H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H],300.05,1000.0,ng/ml,1.0±0.4,ovarian cancer;,3332.78
DDPD00518,Albendazole,CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2,265.331,1150.0,ng/ml,0.50-1.8,"PO, oral;",4334.21
DDPD00520,Caspofungin,CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@H](O)CCN,1093.3131,8700.0,ng/ml,8.7(7.9-9.6),"intravenous injection, IV;",7957.46
DDPD00526,Oxaliplatin,[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1,397.294,814.0,ng/ml,0.814,"intravenous injection, IV;",2048.86
DDPD00526,Oxaliplatin,[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1,397.294,0.33,mg Pt/ml,0.33(0.28-0.38),"intravenous infusion, IV in drop;",0.83
DDPD00526,Oxaliplatin,[H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1,397.294,0.008,mg Pt/ml,0.008(0.004-0.014),"intravenous infusion, IV in drop; Derivative;",0.02
DDPD00529,Foscarnet,OC(=O)P(O)(O)=O,126.0053,10836455.8,ng/ml,86±36,"PO, oral; severe renal function; AIDS,HIV;",86000000.00
DDPD00531,Cyclophosphamide,ClCCN(CCCl)P1(=O)NCCCO1,261.086,31591406.0,ng/ml,121±21,"intravenous injection, IV; breast cancer;",121000000.00
DDPD00535,Cefdinir,[H][C@]12SCC(C=C)=C(N1C(=O)[C@H]2NC(=O)C(=N/O)\C1=CSC(N)=N1)C(O)=O,395.414,1600.0,ng/ml,1.6,"PO, oral;",4046.39
DDPD00535,Cefdinir,[H][C@]12SCC(C=C)=C(N1C(=O)[C@H]2NC(=O)C(=N/O)\C1=CSC(N)=N1)C(O)=O,395.414,2870.0,ng/ml,2.87,"PO, oral;",7258.22
DDPD00535,Cefdinir,[H][C@]12SCC(C=C)=C(N1C(=O)[C@H]2NC(=O)C(=N/O)\C1=CSC(N)=N1)C(O)=O,395.414,2900.0,ng/ml,2.9±1.0,"Capsule, PO, Oral; adults;",7334.09
DDPD00535,Cefdinir,[H][C@]12SCC(C=C)=C(N1C(=O)[C@H]2NC(=O)C(=N/O)\C1=CSC(N)=N1)C(O)=O,395.414,3900.0,ng/ml,3.9±0.6,"Capsule, PO, Oral; Children;",9863.08
DDPD00537,Ciprofloxacin,OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O,331.3415,940.0,ng/ml,0.94,,2836.95
DDPD00537,Ciprofloxacin,OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O,331.3415,2500.0,ng/ml,2.5±1.1,"PO, oral; chronic bronchitis;",7545.09
DDPD00539,Toremifene,CN(C)CCOC1=CC=C(C=C1)C(=C(\CCCl)C1=CC=CC=C1)\C1=CC=CC=C1,405.96,1200.0,ng/ml,1.1-1.3,"PO, oral; adults; breast cancer;",2955.96
DDPD00539,Toremifene,CN(C)CCOC1=CC=C(C=C1)C(=C(\CCCl)C1=CC=CC=C1)\C1=CC=CC=C1,405.96,4250.0,ng/ml,2.7-5.8,"PO, oral; adults; breast cancer;",10469.01
DDPD00540,Nortriptyline,CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12,263.3767,36345984.6,ng/ml,138(40-350),"PO, oral; adults; normal,healthy;",138000000.00
DDPD00541,Vincristine,[H][C@@]12N3CC[C@@]11C4=C(C=C(OC)C(=C4)[C@]4(C[C@H]5C[N@](C[C@](O)(CC)C5)CCC5=C4NC4=CC=CC=C54)C(=O)OC)N(C=O)[C@@]1([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC,824.972,278.42805,ng/ml,~250-425,"intravenous injection, IV;",337.50
DDPD00542,Benazepril,[H][C@@]1(CCC2=CC=CC=C2N(CC(O)=O)C1=O)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC,424.4895,127.34685,ng/ml,~300,"Oral single dose; adults; normal,healthy;",300.00
DDPD00542,Benazepril,[H][C@@]1(CCC2=CC=CC=C2N(CC(O)=O)C1=O)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC,424.4895,212.24475,ng/ml,~500,"Oral single dose; Active metabolite; adults; normal,healthy;",500.00
DDPD00544,Fluorouracil,FC1=CNC(=O)NC1=O,130.0772,1456864.64,ng/ml,11.2,"intravenous infusion, IV in drop; tumor;",11200000.00
DDPD00555,Lamotrigine,NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1,256.091,2500.0,ng/ml,2.5±0.4,"Oral single dose; adults; normal,healthy;",9762.15
DDPD00557,Hydroxyzine,OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1,374.904,72.0,ng/ml,72±11,"PO, oral; Elderly; normal,healthy;",192.05
DDPD00557,Hydroxyzine,OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1,374.904,47.0,ng/ml,47±17,"PO, oral; Children; normal,healthy;",125.37
DDPD00563,Methotrexate,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O,454.4393,499883.23,ng/ml,1.1±0.2,"subcutaneous injection, SC; patients;",1100000.00
DDPD00563,Methotrexate,CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O,454.4393,30901872.4,ng/ml,37-99,"intravenous injection, IV;",68000000.00
DDPD00564,Carbamazepine,NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12,236.2686,1900.0,ng/ml,1.9±0.3,"PO, oral; extended release formulation;",8041.69
DDPD00564,Carbamazepine,NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12,236.2686,11000.0,ng/ml,11.0±2.5,Oral multiple dose;,46557.18
DDPD00564,Carbamazepine,NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12,236.2686,9300.0,ng/ml,9.3(2-18),"PO, oral; immediate release formulation; adults; epilepsy;",39361.98
DDPD00567,Cephalexin,[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O,347.389,7700.0,ng/ml,7.7,,22165.35
DDPD00567,Cephalexin,[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O,347.389,12300.0,ng/ml,12.3,,35406.99
DDPD00567,Cephalexin,[H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O,347.389,28000.0,ng/ml,28±6.4,"Oral single dose; Male, men; adults; normal,healthy;",80601.29
DDPD00571,Propranolol,CC(C)NCC(O)COC1=CC=CC2=C1C=CC=C2,259.3434,18.0,ng/ml,18±15,"PO, oral;",69.41
DDPD00571,Propranolol,CC(C)NCC(O)COC1=CC=CC2=C1C=CC=C2,259.3434,52.0,ng/ml,52±51,"PO, oral;",200.51
DDPD00571,Propranolol,CC(C)NCC(O)COC1=CC=CC2=C1C=CC=C2,259.3434,121.0,ng/ml,121±98,"PO, oral;",466.56
DDPD00571,Propranolol,CC(C)NCC(O)COC1=CC=CC2=C1C=CC=C2,259.3434,245.0,ng/ml,245±110,"PO, oral;",944.69
DDPD00571,Propranolol,CC(C)NCC(O)COC1=CC=CC2=C1C=CC=C2,259.3434,49.0,ng/ml,49±8,"Oral single dose; adults; normal,healthy;",188.94
DDPD00571,Propranolol,CC(C)NCC(O)COC1=CC=CC2=C1C=CC=C2,259.3434,37.0,ng/ml,37±9,"Oral single dose; Active metabolite; adults; normal,healthy;",142.67
DDPD00572,Atropine,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1,289.3694,2.6,ng/ml,2.6±0.5,"IM,intramuscular injection; adults; normal,healthy;",8.99
DDPD00573,Fenoprofen,CC(C(O)=O)C1=CC(OC2=CC=CC=C2)=CC=C1,242.2699,50000.0,ng/ml,50.0,Oral single dose;,206381.40
DDPD00574,Fenfluramine,CCNC(C)CC1=CC=CC(=C1)C(F)(F)F,231.2573,68.0,ng/ml,68.0,"PO, oral; Children;",294.04
DDPD00575,Clonidine,ClC1=CC=CC(Cl)=C1NC1=NCCN1,230.094,0.40072,ng/ml,400.72,"Tablet, PO, oral;",1.74
DDPD00575,Clonidine,ClC1=CC=CC(Cl)=C1NC1=NCCN1,230.094,0.8,ng/ml,0.8,"PO, oral;",3.48
DDPD00575,Clonidine,ClC1=CC=CC(Cl)=C1NC1=NCCN1,230.094,0.35,ng/ml,0.3-0.4,Transdermal preparations;,1.52
DDPD00577,Valaciclovir,CC(C)[C@H](N)C(=O)OCCOCN1C=NC2=C1NC(N)=NC2=O,324.3357,560.0,ng/ml,≤0.56,"Oral single dose; adults; normal,healthy;",1726.61
DDPD00577,Valaciclovir,CC(C)[C@H](N)C(=O)OCCOCN1C=NC2=C1NC(N)=NC2=O,324.3357,4800.0,ng/ml,4.8±1.5,"Oral single dose; adults; normal,healthy;",14799.48
DDPD00582,Voriconazole,C[C@@H](C1=NC=NC=C1F)[C@](O)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1,349.3105,2356.0,ng/ml,2356.0,"PO, oral;",6744.72
DDPD00582,Voriconazole,C[C@@H](C1=NC=NC=C1F)[C@](O)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1,349.3105,3621.0,ng/ml,3621.0,"intravenous injection, IV;",10366.14
DDPD00584,Enalapril,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O,376.4467,69.0,ng/ml,69±37,"PO, oral; young; normal,healthy;",183.29
DDPD00586,Diclofenac,OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl,296.149,2000.0,ng/ml,2.0(1.4-3.0),"Tablet, PO, oral; extended release formulation; adults; normal,healthy;",6753.36
DDPD00586,Diclofenac,OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl,296.149,420.0,ng/ml,0.42±0.17,"Tablet, PO, oral; Sustained Release formulation; adults; normal,healthy;",1418.21
DDPD00601,Linezolid,CC(=O)NC[C@H]1CN(C(=O)O1)C1=CC(F)=C(C=C1)N1CCOCC1,337.3461,16000.0,ng/ml,16±4,"PO, oral;",47429.04
DDPD00601,Linezolid,CC(=O)NC[C@H]1CN(C(=O)O1)C1=CC(F)=C(C=C1)N1CCOCC1,337.3461,15000.0,ng/ml,15±3,"intravenous injection, IV; gram-positive infection;",44464.72
DDPD00602,Ivermectin,CO[C@H]1C[C@@H](O[C@@H](C)[C@@H]1O)O[C@H]1[C@H](C)O[C@H](C[C@@H]1OC)O[C@H]1[C@@H](C)\C=C\C=C2/CO[C@@H]3[C@H](O)C(C)=C[C@@H](C(=O)O[C@H]4C[C@@H](C\C=C1/C)O[C@@]1(CC[C@H](C)[C@@H](C(C)C)O1)C4)[C@]23O.CC[C@@H](C)[C@H]1O[C@@]2(CC[C@@H]1C)O[C@@H]1C\C=C(C)\[C@@H](O[C@@H]3O[C@@H](C)[C@H](O[C@@H]4O[C@@H](C)[C@H](O)[C@@H](OC)C4)[C@@H](OC)C3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O[C@@H](C1)C2)[C@]34O,1736.1589,38.2,ng/ml,38.2±5.8,onchocerciasis;,22.00
DDPD00603,Medroxyprogesterone acetate,[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C,386.5244,88.900612,ng/ml,145-315,"PO, oral;",230.00
DDPD00603,Medroxyprogesterone acetate,[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C,386.5244,40.7783242,ng/ml,33-178,"PO, oral;",105.50
DDPD00603,Medroxyprogesterone acetate,[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C,386.5244,1.812799436,ng/ml,4.69±1.52,"IM,intramuscular injection;",4.69
DDPD00603,Medroxyprogesterone acetate,[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12C,386.5244,1.480388452,ng/ml,3.83±1.56,"subcutaneous injection, SC;",3.83
DDPD00607,Nafcillin,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(OCC)C=CC2=CC=CC=C12)C(O)=O,414.475,30000.0,ng/ml,30.0,"intravenous injection, IV;",72380.72
DDPD00608,Chloroquine,CCN(CC)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12,319.872,975.0,ng/ml,650-1300,"intravenous injection, IV;",3048.09
DDPD00608,Chloroquine,CCN(CC)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12,319.872,96.5,ng/ml,65-128,"PO, oral;",301.68
DDPD00608,Chloroquine,CCN(CC)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12,319.872,76.0,ng/ml,76±14,"PO, oral;",237.60
DDPD00608,Chloroquine,CCN(CC)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12,319.872,268.5,ng/ml,57-480,"IM,intramuscular injection;",839.40
DDPD00608,Chloroquine,CCN(CC)CCCC(C)NC1=CC=NC2=CC(Cl)=CC=C12,319.872,837.0,ng/ml,837±248,"adults; normal,healthy;",2616.67
DDPD00611,Butorphanol,[H][C@@]12CC3=C(C=C(O)C=C3)[C@]3(CCCC[C@@]13O)CCN2CC1CCC1,327.4605,1.4,ng/ml,1.4±0.6,nasal spray;,4.28
DDPD00612,Bisoprolol,CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1,325.443,64.0,ng/ml,64±21,Oral multiple dose;,196.66
DDPD00619,Imatinib,CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1,493.6027,2600.0,ng/ml,2.6±0.8,"PO, oral;",5267.39
DDPD00620,Triamcinolone,[H][C@@]12C[C@@H](O)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,394.4339,5.23,ng/ml,5.23±0.84,"PO, oral;",13.26
DDPD00620,Triamcinolone,[H][C@@]12C[C@@H](O)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,394.4339,0.92,ng/ml,0.92,"inhalation, IH;",2.33
DDPD00620,Triamcinolone,[H][C@@]12C[C@@H](O)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,394.4339,5.33,ng/ml,5.33±1.55,"PO, oral;",13.51
DDPD00623,Fluphenazine,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1,437.522,2.3,ng/ml,2.3±2.1,"PO, oral; immediate release formulation;",5.26
DDPD00623,Fluphenazine,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1,437.522,1.3,ng/ml,1.3,"IM,intramuscular injection; Drug form;",2.97
DDPD00623,Fluphenazine,OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1,437.522,1.1,ng/ml,1.1,"IM,intramuscular injection; Drug form;",2.51
DDPD00624,Testosterone,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O,288.4244,57300.0,ng/ml,573±284,,198665.58
DDPD00625,Efavirenz,FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1,315.675,4000.0,ng/ml,4.0±1.7,"PO, oral;",12671.26
DDPD00627,Niacin,OC(=O)C1=CN=CC=C1,123.1094,60.0,ng/ml,0.06,"PO, oral; RD, renal impairment, Renal disease，including uremia;",487.37
DDPD00627,Niacin,OC(=O)C1=CN=CC=C1,123.1094,2420.0,ng/ml,2.42,"PO, oral; RD, renal impairment, Renal disease，including uremia;",19657.31
DDPD00627,Niacin,OC(=O)C1=CN=CC=C1,123.1094,4220.0,ng/ml,4.22,"PO, oral; RD, renal impairment, Renal disease，including uremia;",34278.45
DDPD00627,Niacin,OC(=O)C1=CN=CC=C1,123.1094,600.0,ng/ml,0.6,"PO, oral; extended release formulation;",4873.71
DDPD00627,Niacin,OC(=O)C1=CN=CC=C1,123.1094,15500.0,ng/ml,15.5,"PO, oral; extended release formulation;",125904.28
DDPD00628,Clorazepic acid,OC(=O)C1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2,314.723,275.0,ng/ml,275±27,"IM,intramuscular injection; Drug form;",873.78
DDPD00630,Alendronic acid,NCCCC(O)(P(O)(O)=O)P(O)(O)=O,249.096,275.0,ng/ml,~275,postmenopausal women;,1103.99
DDPD00630,Alendronic acid,NCCCC(O)(P(O)(O)=O)P(O)(O)=O,249.096,6.7,ng/ml,<5-8.4,"PO, oral; postmenopausal women;",26.90
DDPD00635,Prednisone,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,358.4281,71.5,ng/ml,62-81,"Oral single dose; adults; normal,healthy;",199.48
DDPD00635,Prednisone,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,358.4281,218.5,ng/ml,198-239,"Oral single dose; Active metabolite; adults; normal,healthy;",609.61
DDPD00641,Simvastatin,[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC,418.5662,9.83,ng/ml,9.83,,23.48
DDPD00641,Simvastatin,[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC,418.5662,46.0,ngEq/ml,46±20,"PO, oral; Active metabolite; adults; normal,healthy;",109.90
DDPD00641,Simvastatin,[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC,418.5662,56.0,ngEq/ml,56±25,"PO, oral; Active metabolite; adults; normal,healthy;",133.79
DDPD00654,Latanoprost,CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1,432.5928,0.053,ng/ml,53.0,ophthalmic administration;,0.12
DDPD00656,Trazodone,ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1,371.864,1470.0,ng/ml,1.47±0.16,"PO, oral; food;",3953.06
DDPD00656,Trazodone,ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1,371.864,1880.0,ng/ml,1.88±0.42,"PO, oral; fasting;",5055.61
DDPD00656,Trazodone,ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1,371.864,1500.0,ng/ml,1.5±0.2,"Capsule, PO, Oral; food; adults; normal,healthy;",4033.73
DDPD00660,Metaxalone,CC1=CC(OCC2CNC(=O)O2)=CC(C)=C1,221.2524,1700.0,ng/ml,1.7,Oral single dose; fasting;,7683.53
DDPD00660,Metaxalone,CC1=CC(OCC2CNC(=O)O2)=CC(C)=C1,221.2524,4900.0,ng/ml,4.9,Oral single dose; food;,22146.65
DDPD00661,Verapamil,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1,454.6016,262.5,ng/ml,125-400,"PO, oral; immediate release formulation;",577.43
DDPD00661,Verapamil,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1,454.6016,77.8,ng/ml,77.8,"PO, oral; Optical rotation R;",171.14
DDPD00661,Verapamil,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1,454.6016,16.8,ng/ml,16.8,"PO, oral; Optical rotation S;",36.96
DDPD00661,Verapamil,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1,454.6016,272.0,ng/ml,272.0,"Tablet, PO, oral; immediate release formulation; adults; normal,healthy;",598.33
DDPD00661,Verapamil,COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1,454.6016,141.5,ng/ml,118-165,"Tablet, PO, oral; extended release formulation; adults; normal,healthy;",311.26
DDPD00669,Sumatriptan,CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1,295.4,69.5,ng/ml,69.5（62.8-76.9）,"subcutaneous injection, SC;",235.27
DDPD00669,Sumatriptan,CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1,295.4,16.5,ng/ml,16.5(13.5-20.1),"PO, oral;",55.86
DDPD00669,Sumatriptan,CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1,295.4,12.9,ng/ml,12.9(10.5-15.9),"inhalation, IH;",43.67
DDPD00669,Sumatriptan,CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1,295.4,22.9,ng/ml,22.9(18.4-28.6),Rectal Administration;,77.52
DDPD00669,Sumatriptan,CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1,295.4,54.0,ng/ml,54(27-137),"Oral single dose; adults; normal,healthy;",182.80
DDPD00669,Sumatriptan,CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1,295.4,72.0,ng/ml,72(55-108),"adults; normal,healthy;",243.74
DDPD00671,Cefixime,[H][C@]12SCC(C=C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OCC(O)=O)\C1=CSC(N)=N1)C(O)=O,453.45,2300.0,ng/ml,1.7-2.9,"Capsule, PO, Oral; adults; normal,healthy;",5072.22
DDPD00673,Aprepitant,C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F,534.4267,1600.0,ng/ml,1.6,Oral single dose;,2993.86
DDPD00674,Galantamine,[H][C@]12C[C@@H](O)C=C[C@]11CCN(C)CC3=C1C(O2)=C(OC)C=C3,287.3535,96.0,ng/ml,96±29,"PO, oral; Elderly; normal,healthy;",334.08
DDPD00675,Tamoxifen,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1,371.5146,40.0,ng/ml,40.0,"PO, oral;",107.67
DDPD00675,Tamoxifen,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1,371.5146,15.0,ng/ml,15.0,"PO, oral; Active metabolite;",40.38
DDPD00675,Tamoxifen,CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1,371.5146,120.0,ng/ml,120(67-183),"PO, oral;",323.00
DDPD00678,Losartan,CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1,422.911,225.0,ng/ml,200-250,"PO, oral;",532.03
DDPD00678,Losartan,CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1,422.911,296.0,ng/ml,296±217,"Male, men; normal,healthy;",699.91
DDPD00678,Losartan,CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1,422.911,249.0,ng/ml,249±74,"Active metabolite; Male, men; normal,healthy;",588.78
DDPD00681,Amphotericin B,[H][C@]12C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]1C(O)=O)O2,924.079,1200.0,ng/ml,1.2±0.33,"intravenous infusion, IV in drop;",1298.59
DDPD00681,Amphotericin B,[H][C@]12C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]1C(O)=O)O2,924.079,1700.0,ng/ml,1.7±0.8,"intravenous infusion, IV in drop; Drug form;",1839.67
DDPD00681,Amphotericin B,[H][C@]12C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]1C(O)=O)O2,924.079,83000.0,ng/ml,83±35,"intravenous infusion, IV in drop; Drug form;",89819.16
DDPD00682,Warfarin,CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2,308.3279,900.0,ng/ml,0.9±0.4,"PO, oral; Optical rotation R; patients;",2918.97
DDPD00682,Warfarin,CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2,308.3279,500.0,ng/ml,0.5±0.2,"PO, oral; Optical rotation S; patients;",1621.65
DDPD00683,Midazolam,CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12,325.767,90.0,ng/ml,90.0,"IM,intramuscular injection;",276.27
DDPD00683,Midazolam,CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12,325.767,78.0,ng/ml,78±27,Oral single dose;,239.43
DDPD00683,Midazolam,CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12,325.767,113.0,ng/ml,113±16,,346.87
DDPD00687,Fludrocortisone,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C,380.4504,0.1006,ng/ml,0.0012-0.2,"PO, oral;",0.26
DDPD00688,Mycophenolate mofetil,COC1=C(C\C=C(/C)CCC(=O)OCCN2CCOCC2)C(O)=C2C(=O)OCC2=C1C,433.4947,24500.0,ng/ml,24.5±9.5,Oral single dose;,56517.42
DDPD00688,Mycophenolate mofetil,COC1=C(C\C=C(/C)CCC(=O)OCCN2CCOCC2)C(O)=C2C(=O)OCC2=C1C,433.4947,24100.0,ng/ml,24.1±12.1,"PO, oral; renal transplant;",55594.68
DDPD00695,Furosemide,NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O,330.744,1700.0,ng/ml,1.7±0.9,"Male, men; adults; normal,healthy;",5139.93
DDPD00698,Nitrofurantoin,[O-][N+](=O)C1=CC=C(O1)\C=N\N1CC(=O)NC1=O,238.159,919.0,ng/ml,0.875-0.963,,3858.77
DDPD00698,Nitrofurantoin,[O-][N+](=O)C1=CC=C(O1)\C=N\N1CC(=O)NC1=O,238.159,428.0,ng/ml,428±146,"fasting; adults; normal,healthy;",1797.12
DDPD00700,Eplerenone,[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)C[C@H]1O[C@@]11[C@@]2([H])[C@@H](CC2=CC(=O)CC[C@]12C)C(=O)OC,414.4914,1000.0,ng/ml,1.0±0.3,"PO, oral;",2412.60
DDPD00706,Tamsulosin,CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC(=C(OC)C=C1)S(N)(=O)=O,408.512,4.2,ng/ml,3.1-5.3,"PO, oral;",10.28
DDPD00706,Tamsulosin,CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC(=C(OC)C=C1)S(N)(=O)=O,408.512,3.05,ng/ml,2.5-3.6,"PO, oral;",7.47
DDPD00706,Tamsulosin,CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC(=C(OC)C=C1)S(N)(=O)=O,408.512,16.0,ng/ml,16±5,"Oral single dose; extended release formulation; normal,healthy;",39.17
DDPD00708,Sufentanil,CCC(=O)N(C1=CC=CC=C1)C1(COC)CCN(CCC2=CC=CS2)CC1,386.551,0.075,ng/ml,0.05-0.1,epidural administration;,0.19
DDPD00709,Lamivudine,NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1,229.256,1500.0,ng/ml,1.5±0.5,"PO, oral; AIDS,HIV;",6542.90
DDPD00709,Lamivudine,NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1,229.256,1000.0,ng/ml,1.0(0.86-1.2),"Male, men; normal,healthy;",4361.94
DDPD00710,Ibandronate,CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O,319.2289,4.1,ng/ml,4.1±2.6,"PO, oral; normal,healthy; Male, men;",12.84
DDPD00715,Paroxetine,FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1,329.3654,42.817502,ng/ml,~130,"PO, oral; extensive metabolizers, EM;",130.00
DDPD00715,Paroxetine,FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1,329.3654,72.460388,ng/ml,~220,"PO, oral; poor metabolizers, PM;",220.00
DDPD00717,Norethisterone,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],298.4192,6.375,ng/ml,5.39-7.36,Oral single dose;,21.36
DDPD00717,Norethisterone,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],298.4192,0.8385,ng/ml,617-1060,skin/dermal;,2.81
DDPD00718,Adefovir dipivoxil,CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C(N)N=CN=C12)OCOC(=O)C(C)(C)C,501.4705,18.4,ng/ml,18.4±6.26,"Oral single dose; Hepatitis, Hep; food;",36.69
DDPD00720,Clodronic acid,OP(O)(=O)C(Cl)(Cl)P(O)(O)=O,244.892,16100.0,ng/ml,16.1,"intravenous injection, IV;",65743.27
DDPD00720,Clodronic acid,OP(O)(=O)C(Cl)(Cl)P(O)(O)=O,244.892,12800.0,ng/ml,12.8,"IM,intramuscular injection;",52267.94
DDPD00721,Procaine,CCN(CC)CCOC(=O)C1=CC=C(N)C=C1,236.3101,58.0,ng/ml,58.0,"PO, oral; food;",245.44
DDPD00722,Lisinopril,NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O,405.4879,50.0,ng/ml,50(6.4-343),"PO, oral; adults; hypertension; RD, renal impairment, Renal disease，including uremia;",123.31
DDPD00722,Lisinopril,NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O,405.4879,608231.85,ng/ml,1-2,Oral single dose; immediate release formulation;,1500000.00
DDPD00722,Lisinopril,NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O,405.4879,385213.505,ng/ml,0.7-1.2,extended release formulation;,950000.00
DDPD00727,Nitroglycerin,[O-][N+](=O)OCC(CO[N+]([O-])=O)O[N+]([O-])=O,227.0865,2.56,ng/ml,2.56,sublingual;,11.27
DDPD00727,Nitroglycerin,[O-][N+](=O)OCC(CO[N+]([O-])=O)O[N+]([O-])=O,227.0865,2.1,ng/ml,2.1,sublingual;,9.25
DDPD00727,Nitroglycerin,[O-][N+](=O)OCC(CO[N+]([O-])=O)O[N+]([O-])=O,227.0865,1.9,ng/ml,1.9±1.6,sublingual;,8.37
DDPD00727,Nitroglycerin,[O-][N+](=O)OCC(CO[N+]([O-])=O)O[N+]([O-])=O,227.0865,3.4,ng/ml,3.4±1.7,"intravenous injection, IV;",14.97
DDPD00728,Rocuronium,[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](O)[C@H](C[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1,529.7742,1100.0,ng/ml,0.8-1.4,"intravenous injection, IV;",2076.36
DDPD00734,Risperidone,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1,410.4845,10.0,ng/ml,10.0,"PO, oral; schizophrenia;",24.36
DDPD00734,Risperidone,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1,410.4845,45.0,ng/ml,45.0,"PO, oral; Active metabolite; schizophrenia;",109.63
DDPD00736,Esomeprazole,COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1,345.416,1554372.0,ng/ml,4.5(3.8-5.7),"PO, oral; normal,healthy;",4500000.00
DDPD00736,Esomeprazole,COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1,345.416,234882.88,ng/ml,0.68±0.43,"PO, oral; normal,healthy; extensive metabolizers, EM;",680000.00
DDPD00736,Esomeprazole,COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1,345.416,1208956.0,ng/ml,3.5±1.4,"PO, oral; normal,healthy; poor metabolizers, PM;",3500000.00
DDPD00740,Riluzole,NC1=NC2=C(S1)C=C(OC(F)(F)F)C=C2,234.198,173.0,ng/ml,173±72,"PO, oral;",738.69
DDPD00741,Hydrocortisone,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,362.4599,11.848814131,ng/ml,32.69,"PO, oral;",32.69
DDPD00741,Hydrocortisone,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,362.4599,25.665785519,ng/ml,70.81,"PO, oral;",70.81
DDPD00758,Clopidogrel,[H][C@@](N1CCC2=C(C1)C=CS2)(C(=O)OC)C1=CC=CC=C1Cl,321.822,2.01,ng/ml,2.01±2.0,"PO, oral;",6.25
DDPD00758,Clopidogrel,[H][C@@](N1CCC2=C(C1)C=CS2)(C(=O)OC)C1=CC=CC=C1Cl,321.822,31.3,ng/ml,31.3±13,"PO, oral; poor metabolizers, PM;",97.26
DDPD00758,Clopidogrel,[H][C@@](N1CCC2=C(C1)C=CS2)(C(=O)OC)C1=CC=CC=C1Cl,321.822,60.8,ng/ml,60.8±34.3,"PO, oral; high-fat meal;",188.92
DDPD00759,Tetracycline,[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O,444.4346,2300.0,ng/ml,2.3±0.2,"PO, oral; fasting;",5175.11
DDPD00759,Tetracycline,[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O,444.4346,16400.0,ng/ml,16.4±1.2,"intravenous injection, IV;",36900.82
DDPD00762,Irinotecan,CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12,586.678,1660.0,ng/ml,1660.0,tumor;,2829.49
DDPD00762,Irinotecan,CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12,586.678,3392.0,ng/ml,3392.0,tumor;,5781.71
DDPD00762,Irinotecan,CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12,586.678,1700.0,ng/ml,1.7±0.8,"intravenous infusion, IV in drop; solid tumors;",2897.67
DDPD00762,Irinotecan,CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12,586.678,26.0,ng/ml,26±12,"intravenous infusion, IV in drop; Active metabolite; solid tumors;",44.32
DDPD00766,Clavulanic acid,[H][C@@]12CC(=O)N1[C@@H](C(O)=O)\C(O2)=C\CO,199.1608,2098.0,ng/ml,2.098±0.441,"PO, oral;",10534.20
DDPD00768,Olopatadine,CN(C)CC\C=C1\C2=CC=CC=C2COC2=C1C=C(CC(O)=O)C=C2,337.4122,1.6,ng/ml,1.6±0.9,"ophthalmic administration; normal,healthy;",4.74
DDPD00768,Olopatadine,CN(C)CC\C=C1\C2=CC=CC=C2COC2=C1C=C(CC(O)=O)C=C2,337.4122,6.0,ng/ml,6.0±8.99,"inhalation, IH; normal,healthy;",17.78
DDPD00768,Olopatadine,CN(C)CC\C=C1\C2=CC=CC=C2COC2=C1C=C(CC(O)=O)C=C2,337.4122,23.3,ng/ml,23.3±6.2,"inhalation, IH; allergic rhinitis;",69.06
DDPD00773,Etoposide,[H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(O)C(OC)=C1)C1=CC3=C(OCO3)C=C1[C@H]2O[C@@H]1O[C@]2([H])CO[C@@H](C)O[C@@]2([H])[C@H](O)[C@H]1O,588.5566,2700.0,ng/ml,2.7,"intravenous infusion, IV in drop;",4587.49
DDPD00773,Etoposide,[H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(O)C(OC)=C1)C1=CC3=C(OCO3)C=C1[C@H]2O[C@@H]1O[C@]2([H])CO[C@@H](C)O[C@@]2([H])[C@H](O)[C@H]1O,588.5566,4700.0,ng/ml,4.7,"intravenous infusion, IV in drop; hematological toxicity;",7985.64
DDPD00776,Oxcarbazepine,NC(=O)N1C2=CC=CC=C2CC(=O)C2=C1C=CC=C2,252.268,34.0,ng/ml,34.0,Oral single dose;,134.78
DDPD00776,Oxcarbazepine,NC(=O)N1C2=CC=CC=C2CC(=O)C2=C1C=CC=C2,252.268,8500.0,ng/ml,8.5±2.0,"PO, oral;",33694.33
DDPD00780,Phenelzine,NNCCC1=CC=CC=C1,136.1943,19.8,ng/ml,19.8,"PO, oral;",145.38
DDPD00783,Estradiol,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,272.382,0.174,ng/ml,174.0,Transdermal preparations;,0.64
DDPD00783,Estradiol,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,272.382,0.054,ng/ml,54.0,skin/dermal;,0.20
DDPD00783,Estradiol,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,272.382,0.063,ng/ml,63.0,Vaginal Administration;,0.23
DDPD00783,Estradiol,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,272.382,0.0128,ng/ml,12.8±16.6,Vaginal Administration;,0.05
DDPD00787,Acyclovir,NC1=NC(=O)C2=C(N1)N(COCCO)C=N2,225.2046,625.1,ng/ml,593.7-656.5,,2775.70
DDPD00787,Acyclovir,NC1=NC(=O)C2=C(N1)N(COCCO)C=N2,225.2046,1002160.47,ng/ml,3.5-5.4,Oral multiple dose;,4450000.00
DDPD00788,Naproxen,COC1=CC2=C(C=C1)C=C(C=C2)[C@H](C)C(O)=O,230.2592,95700.0,ng/ml,94-97.4,"PO, oral; Rectal Administration;",415618.57
DDPD00788,Naproxen,COC1=CC2=C(C=C1)C=C(C=C2)[C@H](C)C(O)=O,230.2592,37.0,null,37.0,"Tablet, PO, oral; immediate release formulation; adults;",160.69
DDPD00788,Naproxen,COC1=CC2=C(C=C1)C=C(C=C2)[C@H](C)C(O)=O,230.2592,94.0,null,94.0,"Tablet, PO, oral; extended release formulation; adults;",408.24
DDPD00788,Naproxen,COC1=CC2=C(C=C1)C=C(C=C2)[C@H](C)C(O)=O,230.2592,55000.0,ng/ml,55±14,Liquid; Children; patients;,238861.25
DDPD00794,Primidone,CCC1(C(=O)NCNC1=O)C1=CC=CC=C1,218.2518,2700.0,ng/ml,2.7±0.4,Oral single dose;,12371.03
DDPD00798,Gentamicin,CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1,477.5954,5000.0,ng/ml,5.0±0.4,"intravenous injection, IV; adults; normal,healthy;",10469.11
DDPD00798,Gentamicin,CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1,477.5954,4900.0,ng/ml,4.9±0.5,"intravenous infusion, IV in drop; adults; normal,healthy;",10259.73
DDPD00802,Alfentanil,CCN1N=NN(CCN2CCC(COC)(CC2)N(C(=O)CC)C2=CC=CC=C2)C1=O,416.5172,150.0,ng/ml,100-200,,360.13
DDPD00802,Alfentanil,CCN1N=NN(CCN2CCC(COC)(CC2)N(C(=O)CC)C2=CC=CC=C2)C1=O,416.5172,325.0,ng/ml,310-340,,780.28
DDPD00808,Indapamide,CC1CC2=CC=CC=C2N1NC(=O)C1=CC(=C(Cl)C=C1)S(N)(=O)=O,365.835,363.0,ng/ml,363.0,"PO, oral;",992.25
DDPD00811,Ribavirin,NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,244.2047,3687490.97,ng/ml,15.1±12.8,"PO, oral; adults; HCV-positive;",15100000.00
DDPD00811,Ribavirin,NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,244.2047,2710672.17,ng/ml,11.1±1.2,"Capsule, PO, Oral; adults; AIDS,HIV;",11100000.00
DDPD00813,Fentanyl,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,336.4705,0.4,ng/ml,0.4±0.1,"Tablet, PO, oral;",1.19
DDPD00813,Fentanyl,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,336.4705,0.2,ng/ml,0.20±0.06,sublingual;,0.59
DDPD00813,Fentanyl,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,336.4705,1.61,ng/ml,1.61±0.60,sublingual; increasing doses;,4.78
DDPD00813,Fentanyl,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,336.4705,0.24,ng/ml,0.24±0.20,Transdermal preparations;,0.71
DDPD00813,Fentanyl,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,336.4705,0.815,ng/ml,815±301,nasal spray;,2.42
DDPD00813,Fentanyl,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,336.4705,0.815,ng/ml,815±301,,2.42
DDPD00813,Fentanyl,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,336.4705,0.8,ng/ml,0.8±0.3,buccal;,2.38
DDPD00813,Fentanyl,CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,336.4705,1.4,ng/ml,1.4±0.5,Transdermal preparations;,4.16
DDPD00814,Meloxicam,CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=C(C=CC=C2)S1(=O)=O,351.401,1900.0,ng/ml,1.9±0.6,"Capsule, PO, Oral;",5406.93
DDPD00818,Propofol,CC(C)C1=CC=CC(C(C)C)=C1O,178.2707,3500.0,ng/ml,3.5±0.06,"intravenous injection, IV;",19633.06
DDPD00818,Propofol,CC(C)C1=CC=CC(C(C)C)=C1O,178.2707,1100.0,ng/ml,1.1±0.4,"PO, oral; patients;",6170.39
DDPD00820,Tadalafil,[H][C@]12CC3=C(NC4=CC=CC=C34)[C@H](N1C(=O)CN(C)C2=O)C1=CC2=C(OCO2)C=C1,389.404,378.0,ng/ml,378.0,Oral single dose;,970.71
DDPD00829,Diazepam,CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1,284.74,317.0,ng/ml,317±27,"Oral single dose; adults; normal,healthy;",1113.30
DDPD00829,Diazepam,CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1,284.74,400.0,ng/ml,~400,"Rectal Administration; adults; normal,healthy;",1404.79
DDPD00829,Diazepam,CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1,284.74,450.0,ng/ml,400-500,"adults; normal,healthy;",1580.39
DDPD00842,Oxazepam,OC1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2,286.713,450000000.0,ng/ml,450.0,"PO, oral;",1569513764.64
DDPD00843,Donepezil,COC1=C(OC)C=C2C(=O)C(CC3CCN(CC4=CC=CC=C4)CC3)CC2=C1,379.492,8.34,ng/ml,8.34,"Tablet, PO, oral;",21.98
DDPD00843,Donepezil,COC1=C(OC)C=C2C(=O)C(CC3CCN(CC4=CC=CC=C4)CC3)CC2=C1,379.492,30.8,ng/ml,30.8±4.2,"PO, oral;",81.16
DDPD00845,Clofazimine,CC(C)N=C1C=C2N(C3=CC=C(Cl)C=C3)C3=C(C=CC=C3)N=C2C=C1NC1=CC=C(Cl)C=C1,473.396,410.0,ng/ml,0.41,"PO, oral; food;",866.08
DDPD00852,Pseudoephedrine,CN[C@@H](C)[C@@H](O)C1=CC=CC=C1,165.2322,246.3,null,246.3±10.5,"PO, oral;",1490.63
DDPD00852,Pseudoephedrine,CN[C@@H](C)[C@@H](O)C1=CC=CC=C1,165.2322,246.3,ng/ml,246.3±10.5,"PO, oral; food;",1490.63
DDPD00852,Pseudoephedrine,CN[C@@H](C)[C@@H](O)C1=CC=CC=C1,165.2322,272.5,ng/ml,272.5±13.4,"PO, oral; fasting;",1649.19
DDPD00852,Pseudoephedrine,CN[C@@H](C)[C@@H](O)C1=CC=CC=C1,165.2322,268.5,ng/ml,177-360,Oral single dose; immediate release formulation;,1624.99
DDPD00852,Pseudoephedrine,CN[C@@H](C)[C@@H](O)C1=CC=CC=C1,165.2322,289.5,ng/ml,265-314,Oral single dose; extended release formulation;,1752.08
DDPD00857,Terbinafine,CN(C\C=C\C#CC(C)(C)C)CC1=CC=CC2=CC=CC=C12,291.4299,1000.0,ng/ml,1.0,,3431.36
DDPD00857,Terbinafine,CN(C\C=C\C#CC(C)(C)C)CC1=CC=CC2=CC=CC=C12,291.4299,999.0,ng/cm2,949-1049,skin/dermal;,3427.93
DDPD00860,Prednisolone,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,360.444,728.0,ng/ml,113-1343,"PO, oral;",2019.73
DDPD00860,Prednisolone,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,360.444,458.0,ng/ml,458±150,"PO, oral; Male, men; adults; normal,healthy;",1270.66
DDPD00863,Ranitidine,CNC(NCCSCC1=CC=C(CN(C)C)O1)=C[N+]([O-])=O,314.4,462.0,ng/ml,462±54,"Oral single dose; adults; normal,healthy;",1469.47
DDPD00864,Tacrolimus,CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC,804.0182,31.2,ng/ml,31.2±10.1,"Oral single dose; adults; normal,healthy;",38.81
DDPD00868,Benzonatate,CCCCNC1=CC=C(C=C1)C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC,603.7419,1063.0,ng/ml,1063±460,"PO, oral;",1760.69
DDPD00877,Sirolimus,[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC,914.187,67.0,ng/ml,67±23,"Oral single dose; normal,healthy;",73.29
DDPD00877,Sirolimus,[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC,914.187,152.0,ng/ml,94-210,Oral multiple dose; renal transplant;,166.27
DDPD00878,Chlorhexidine,ClC1=CC=C(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC2=CC=C(Cl)C=C2)C=C1,505.447,0.206,ng/mg,0.206,Oral single dose;,0.41
DDPD00879,Emtricitabine,NC1=NC(=O)N(C=C1F)[C@@H]1CS[C@H](CO)O1,247.247,1800.0,ng/ml,1.8±0.7,,7280.17
DDPD00879,Emtricitabine,NC1=NC(=O)N(C=C1F)[C@@H]1CS[C@H](CO)O1,247.247,1278.0,ng/ml,1.278±0.497,food;,5168.92
DDPD00881,Quinapril,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC=CC=C2C[C@H]1C(O)=O,438.5161,1526.0,ng/ml,1526.0,"PO, oral; Male, men; normal,healthy;",3479.92
DDPD00881,Quinapril,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC=CC=C2C[C@H]1C(O)=O,438.5161,923.0,ng/ml,923±277,"intravenous injection, IV; Drug form;",2104.83
DDPD00881,Quinapril,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC=CC=C2C[C@H]1C(O)=O,438.5161,207.0,ng/ml,207±89,"PO, oral;",472.05
DDPD00883,Isosorbide dinitrate,[H][C@]12OC[C@H](O[N+]([O-])=O)[C@@]1([H])OC[C@H]2O[N+]([O-])=O,236.1363,9.9177246,ng/ml,42(59-166),"PO, oral; immediate release formulation;",42.00
DDPD00883,Isosorbide dinitrate,[H][C@]12OC[C@H](O[N+]([O-])=O)[C@@]1([H])OC[C@H]2O[N+]([O-])=O,236.1363,48.8802141,ng/ml,207(197-335),"PO, oral; Active metabolite; immediate release formulation;",207.00
DDPD00883,Isosorbide dinitrate,[H][C@]12OC[C@H](O[N+]([O-])=O)[C@@]1([H])OC[C@H]2O[N+]([O-])=O,236.1363,212.52267,ng/ml,900(790-1080),"PO, oral; Active metabolite; immediate release formulation;",900.00
DDPD00883,Isosorbide dinitrate,[H][C@]12OC[C@H](O[N+]([O-])=O)[C@@]1([H])OC[C@H]2O[N+]([O-])=O,236.1363,0.0,ng/ml,~0,"PO, oral; Sustained Release formulation;",0.00
DDPD00883,Isosorbide dinitrate,[H][C@]12OC[C@H](O[N+]([O-])=O)[C@@]1([H])OC[C@H]2O[N+]([O-])=O,236.1363,6.6118164,ng/ml,28(23-33),"PO, oral; Active metabolite; Sustained Release formulation;",28.00
DDPD00883,Isosorbide dinitrate,[H][C@]12OC[C@H](O[N+]([O-])=O)[C@@]1([H])OC[C@H]2O[N+]([O-])=O,236.1363,41.3238525,ng/ml,175(154-267),"PO, oral; Active metabolite; Sustained Release formulation;",175.00
DDPD00884,Risedronic acid,OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)(O)=O,283.1123,2.8,ng/ml,2.8±0.3,"PO, oral; Male, men; normal,healthy;",9.89
DDPD00889,Granisetron,CN1N=C(C(=O)N[C@@H]2C[C@@H]3CCC[C@H](C2)N3C)C2=C1C=CC=C2,312.417,6.0,ng/ml,6.0(0.6-31),Oral single dose; tumor;,19.21
DDPD00889,Granisetron,CN1N=C(C(=O)N[C@@H]2C[C@@H]3CCC[C@H](C2)N3C)C2=C1C=CC=C2,312.417,64.0,ng/ml,64(18-176),"intravenous injection, IV; tumor;",204.85
DDPD00899,Remifentanil,CCC(=O)N(C1=CC=CC=C1)C1(CCN(CCC(=O)OC)CC1)C(=O)OC,376.4467,20.0,ng/ml,~20,"intravenous injection, IV;",53.13
DDPD00900,Didanosine,OC[C@@H]1CC[C@@H](O1)N1C=NC2=C1NC=NC2=O,236.2273,1500.0,ng/ml,1.5±0.7,"Tablet, PO, oral; fasting; extended release formulation; AIDS,HIV;",6349.82
DDPD00900,Didanosine,OC[C@@H]1CC[C@@H](O1)N1C=NC2=C1NC=NC2=O,236.2273,930.0,ng/ml,0.93±0.43,"PO, oral; fasting; extended release formulation; AIDS,HIV;",3936.89
DDPD00904,Ondansetron,CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2,293.363,39.0,ng/ml,39(31-48),"PO, oral; adults; normal,healthy;",132.94
DDPD00904,Ondansetron,CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2,293.363,102.0,ng/ml,102(64-136),,347.69
DDPD00905,Bimatoprost,CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1,415.5656,0.08,ng/ml,0.08,ophthalmic administration;,0.19
DDPD00905,Bimatoprost,CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1,415.5656,12.2,ng/ml,12.2,different study;,29.36
DDPD00906,Tiagabine,CC1=C(SC=C1)C(=CCCN1CCC[C@H](C1)C(O)=O)C1=C(C)C=CS1,375.548,122.0,ng/ml,122±36,"Oral single dose; adults; normal,healthy;",324.86
DDPD00906,Tiagabine,CC1=C(SC=C1)C(=CCCN1CCC[C@H](C1)C(O)=O)C1=C(C)C=CS1,375.548,69.0,ng/ml,69±22,"Oral multiple dose; adults; normal,healthy;",183.73
DDPD00908,Quinidine,[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,324.4168,1300.0,ng/ml,~1.3,"PO, oral; immediate release formulation; adults; normal,healthy;",4007.19
DDPD00908,Quinidine,[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,324.4168,530.0,ng/ml,0.53±0.22,"PO, oral; extended release formulation; adults; normal,healthy;",1633.70
DDPD00908,Quinidine,[H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1,324.4168,2900.0,ng/ml,2.9±1.0,"intravenous injection, IV; adults; normal,healthy;",8939.12
DDPD00909,Zonisamide,NS(=O)(=O)CC1=NOC2=CC=CC=C12,212.226,28000.0,ng/ml,28±4,"PO, oral; adults; normal,healthy;",131934.82
DDPD00912,Repaglinide,CCOC1=C(C=CC(CC(=O)N[C@@H](CC(C)C)C2=CC=CC=C2N2CCCCC2)=C1)C(O)=O,452.5857,47.0,ng/ml,47±24,"Male, men; adults; normal,healthy;",103.85
DDPD00916,Metronidazole,CC1=NC=C(N1CCO)[N+]([O-])=O,171.154,35000.0,ng/ml,30-40,"intravenous infusion, IV in drop;",204494.20
DDPD00916,Metronidazole,CC1=NC=C(N1CCO)[N+]([O-])=O,171.154,26000.0,ng/ml,26.0,,151909.98
DDPD00916,Metronidazole,CC1=NC=C(N1CCO)[N+]([O-])=O,171.154,10500.0,ng/ml,8-13,Oral single dose;,61348.26
DDPD00916,Metronidazole,CC1=NC=C(N1CCO)[N+]([O-])=O,171.154,19800.0,ng/ml,19.8,,115685.29
DDPD00916,Metronidazole,CC1=NC=C(N1CCO)[N+]([O-])=O,171.154,1900.0,ng/ml,1.9±0.2,Vaginal Administration;,11101.11
DDPD00916,Metronidazole,CC1=NC=C(N1CCO)[N+]([O-])=O,171.154,27000.0,ng/ml,27(11-41),"intravenous infusion, IV in drop;",157752.67
DDPD00921,Buprenorphine,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4,467.6401,0.78,ng/ml,0.78,,1.67
DDPD00921,Buprenorphine,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4,467.6401,3.6,ng/ml,3.6±3.0,"IM,intramuscular injection;",7.70
DDPD00921,Buprenorphine,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4,467.6401,3.3,ng/ml,3.3±0.8,"subcutaneous injection, SC;",7.06
DDPD00921,Buprenorphine,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4,467.6401,2.0,ng/ml,2.0±0.6,buccal;,4.28
DDPD00924,Cyclobenzaprine,CN(C)CCC=C1C2=CC=CC=C2C=CC2=CC=CC=C12,275.3874,20.0,ng/ml,5-35,"PO, oral;",72.62
DDPD00929,Misoprostol,CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC,382.5341,2.683,ng/ml,2.6830±1.2161,"PO, oral;",7.01
DDPD00929,Misoprostol,CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC,382.5341,2.4391,ng/ml,2.4391±1.1567,sublingual;,6.38
DDPD00929,Misoprostol,CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC,382.5341,1.3611,ng/ml,1.3611±0.3436,buccal;,3.56
DDPD00938,Salmeterol,OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1,415.5656,0.047897,ng/ml,47.897,"inhalation, IH;",0.12
DDPD00945,Acetylsalicylic acid,CC(=O)OC1=CC=CC=C1C(O)=O,180.1574,24000.0,ng/ml,24±4,Oral single dose;,133216.84
DDPD00947,Fulvestrant,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@@]21[H],606.78,8.2,ng/ml,8.2±5.2,"IM,intramuscular injection; postmenopausal women; breast cancer;",13.51
DDPD00950,Fexofenadine,CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,501.6564,299.0,ng/ml,299,Oral multiple dose;,596.03
DDPD00950,Fexofenadine,CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,501.6564,286.0,ng/ml,286±143,"PO, oral;",570.11
DDPD00951,Isoniazid,NNC(=O)C1=CC=NC=C1,137.1393,5400.0,ng/ml,5.4±2.0,"PO, oral; Drug form; normal,healthy;",39376.02
DDPD00951,Isoniazid,NNC(=O)C1=CC=NC=C1,137.1393,7100.0,ng/ml,7.1±1.9,"PO, oral; Drug form; normal,healthy;",51772.18
DDPD00953,Rizatriptan,CN(C)CCC1=CNC2=C1C=C(CN1C=NC=N1)C=C2,269.3449,20.0,ng/ml,20±4.9,"Oral single dose; adults; normal,healthy;",74.25
DDPD00953,Rizatriptan,CN(C)CCC1=CNC2=C1C=C(CN1C=NC=N1)C=C2,269.3449,37.0,ng/ml,37±13,"Oral multiple dose; adults; normal,healthy;",137.37
DDPD00956,Hydrocodone,[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O,299.3642,6250000.0,ng,2.5-10,Liquid;,20877579.88
DDPD00956,Hydrocodone,[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O,299.3642,70000000.0,ng,20-120,"Tablet, PO, oral; extended release formulation;",233828894.70
DDPD00956,Hydrocodone,[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O,299.3642,7937500.0,ng,3.175-12.7,Liquid; food;,26514526.45
DDPD00956,Hydrocodone,[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O,299.3642,88900000.0,ng,25.4-152.4,"Tablet, PO, oral; extended release formulation; food;",296962696.27
DDPD00956,Hydrocodone,[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O,299.3642,30.0,ng/ml,30±9.4,"PO, oral; extensive metabolizers, EM;",100.21
DDPD00956,Hydrocodone,[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O,299.3642,27.0,ng/ml,27±5.9,"PO, oral; poor metabolizers, PM;",90.19
DDPD00957,Norgestimate,[H][C@@]12CC[C@@](OC(C)=O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CC\C(C=C3CC[C@@]21[H])=N/O,369.4971,1.82,ng/ml,1.82,"PO, oral; Active metabolite;",4.93
DDPD00957,Norgestimate,[H][C@@]12CC[C@@](OC(C)=O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CC\C(C=C3CC[C@@]21[H])=N/O,369.4971,2.79,ng/ml,2.79,"PO, oral; Active metabolite;",7.55
DDPD00958,Carboplatin,[H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H],371.254,39000.0,ng/ml,39±17,adults; ovarian cancer;,105049.37
DDPD00959,Methylprednisolone,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C,374.4706,178.0,ng/ml,178±44,"PO, oral; Male, men; adults; normal,healthy;",475.34
DDPD00959,Methylprednisolone,[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C,374.4706,225.0,ng/ml,225±44,"intravenous injection, IV; Male, men; adults; normal,healthy;",600.85
DDPD00962,Zaleplon,CCN(C(C)=O)C1=CC=CC(=C1)C1=CC=NC2=C(C=NN12)C#N,305.3339,26.0,ng/ml,26±4.4,"Oral single dose; normal,healthy;",85.15
DDPD00964,Apraclonidine,NC1=CC(Cl)=C(NC2=NCCN2)C(Cl)=C1,245.109,0.9,ng/ml,0.9,ophthalmic administration;,3.67
DDPD00973,Ezetimibe,[H][C@]1(CC[C@H](O)C2=CC=C(F)C=C2)C(=O)N(C2=CC=C(F)C=C2)[C@]1([H])C1=CC=C(O)C=C1,409.4252,4.45,ng/ml,3.4-5.5,Oral single dose; adults; fasting;,10.87
DDPD00973,Ezetimibe,[H][C@]1(CC[C@H](O)C2=CC=C(F)C=C2)C(=O)N(C2=CC=C(F)C=C2)[C@]1([H])C1=CC=C(O)C=C1,409.4252,58.0,ng/ml,45-71,"PO, oral; Active metabolite;",141.66
DDPD00973,Ezetimibe,[H][C@]1(CC[C@H](O)C2=CC=C(F)C=C2)C(=O)N(C2=CC=C(F)C=C2)[C@]1([H])C1=CC=C(O)C=C1,409.4252,122.0,ng/ml,122.0,"PO, oral;",297.98
DDPD00976,Telithromycin,[H][C@@]12[C@@H](C)C(=O)[C@H](C)C[C@@](C)(OC)[C@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@H](CC)[C@@]1(C)OC(=O)N2CCCCN1C=NC(=C1)C1=CC=CN=C1,812.018,2230.0,ng/ml,2.23,"PO, oral;",2746.24
DDPD00977,Ethinylestradiol,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,296.4034,0.0741,ng/ml,74.1±35.6,"PO, oral;",0.25
DDPD00977,Ethinylestradiol,[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,296.4034,0.0288,ng/ml,28.8±10.3,Transdermal preparations;,0.10
DDPD00982,Isotretinoin,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O,300.4351,292.5,ng/ml,74-511,"PO, oral;",973.59
DDPD00982,Isotretinoin,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O,300.4351,314.0,ng/ml,314,"PO, oral; fasting;",1045.15
DDPD00982,Isotretinoin,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O,300.4351,395.0,ng/ml,395,"PO, oral; high-fat meal;",1314.76
DDPD00982,Isotretinoin,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O,300.4351,208.0,ng/ml,208±92,"PO, oral;",692.33
DDPD00982,Isotretinoin,C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O,300.4351,473.0,ng/ml,473±171,"PO, oral; Active metabolite;",1574.38
DDPD00983,Formoterol,COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1,344.4049,2.2e-05,ng/ml,22,"inhalation, IH; adults; normal,healthy;",0.00
DDPD00983,Formoterol,COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1,344.4049,2.2e-05,ng/ml,22,adults; asthma;,0.00
DDPD00983,Formoterol,COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1,344.4049,4.1e-05,ng/ml,41,adults; asthma;,0.00
DDPD00987,Cytarabine,NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,243.2166,5000.0,ng/ml,~5,"intravenous injection, IV; leukemia; malignant solid tumors;",20557.81
DDPD00987,Cytarabine,NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,243.2166,75.0,ng/ml,0.05-0.1,"intravenous infusion, IV in drop; leukemia; malignant solid tumors;",308.37
DDPD00989,Rivastigmine,CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C,250.3367,26.0,ng/ml,26±10,"Capsule, PO, Oral;",103.86
DDPD00993,Azathioprine,CN1C=NC(=C1SC1=NC=NC2=C1NC=N2)[N+]([O-])=O,277.263,55.0,ng/ml,20-90,"PO, oral; Active metabolite; renal transplant;",198.37
DDPD00996,Gabapentin,NCC1(CC(O)=O)CCCCC1,171.2368,4000.0,ng/ml,4.0,"PO, oral; adults; normal,healthy;",23359.46
DDPD00997,Doxorubicin,COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O,543.5193,950.0,ng/ml,~950,"intravenous infusion, IV in drop; depression;",1747.87
DDPD00997,Doxorubicin,COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O,543.5193,519.0,ng/ml,30-1008,"intravenous infusion, IV in drop; Active metabolite; depression;",954.89
DDPD00997,Doxorubicin,COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O,543.5193,6.0,ng/ml,6.0±3.2,"intravenous infusion, IV in drop; Advanced tumors;",11.04
DDPD00997,Doxorubicin,COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O,543.5193,5.0,ng/ml,5.0±3.5,"intravenous infusion, IV in drop; Active metabolite; Advanced tumors;",9.20
DDPD00999,Hydrochlorothiazide,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,297.739,280.0,ng/ml,70-490,"PO, oral;",940.42
DDPD00999,Hydrochlorothiazide,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,297.739,224.0,ng/ml,56-392,"PO, oral; food;",752.34
DDPD00999,Hydrochlorothiazide,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,297.739,75.0,ng/ml,75±17,"Oral single dose; adults; normal,healthy;",251.90
DDPD00999,Hydrochlorothiazide,NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1,297.739,91.0,ng/ml,91±0.2,"Oral multiple dose; adults; normal,healthy;",305.64
DDPD01001,Salbutamol,CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1,239.3107,3.0,ng/ml,3,"PO, oral; Active metabolite;",12.54
DDPD01001,Salbutamol,CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1,239.3107,3.6,ng/ml,3.6(1.9-5.9),Oral single dose; Optical rotation R;,15.04
DDPD01001,Salbutamol,CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1,239.3107,11.4,ng/ml,11.4(7.1-16.2),Oral single dose; Optical rotation S;,47.64
DDPD01002,Levobupivacaine,CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C,288.4277,1200.0,ng/ml,1.2,epidural administration;,4160.49
DDPD01004,Ganciclovir,NC1=NC2=C(N=CN2COC(CO)CO)C(=O)N1,255.2306,1200.0,ng/ml,1.2±0.4,"intravenous infusion, IV in drop; food;",4701.63
DDPD01004,Ganciclovir,NC1=NC2=C(N=CN2COC(CO)CO)C(=O)N1,255.2306,6600.0,ng/ml,6.6±1.8,,25858.97
DDPD01005,Hydroxyurea,NC(=O)NO,76.0547,76587082.9,ng/ml,1007±371,"intravenous injection, IV; solid tumors;",1007000000.00
DDPD01005,Hydroxyurea,NC(=O)NO,76.0547,60387431.8,ng/ml,794±241,"PO, oral; solid tumors;",794000000.00
DDPD01006,Letrozole,N#CC1=CC=C(C=C1)C(N1C=NC=N1)C1=CC=C(C=C1)C#N,285.3027,29.6714808,ng/ml,104,"PO, oral;",104.00
DDPD01006,Letrozole,N#CC1=CC=C(C=C1)C(N1C=NC=N1)C1=CC=C(C=C1)C#N,285.3027,32.8098105,ng/ml,115.0,"postmenopausal women; normal,healthy;",115.00
DDPD01008,Busulfan,CS(=O)(=O)OCCCCOS(C)(=O)=O,246.302,30.0,ng/ml,30,Oral single dose; patients;,121.80
DDPD01008,Busulfan,CS(=O)(=O)OCCCCOS(C)(=O)=O,246.302,65.0,ng/ml,65±27,Oral single dose; Chronic myelogenous leukemia;,263.90
DDPD01008,Busulfan,CS(=O)(=O)OCCCCOS(C)(=O)=O,246.302,949.0,ng/ml,949±278,Oral single dose; bone marrow transplant;,3852.99
DDPD01012,Cinacalcet,C[C@@H](NCCCC1=CC(=CC=C1)C(F)(F)F)C1=CC=CC2=CC=CC=C12,357.412,10.6,ng/ml,10.6±2.8,Oral single dose;,29.66
DDPD01013,Clobetasol propionate,[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,466.97,0.059,ng/ml,59±36,skin/dermal;,0.13
DDPD01013,Clobetasol propionate,[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,466.97,0.0563,ng/ml,56.3±104.7,ointment;,0.12
DDPD01015,Sulfamethoxazole,CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1,253.278,62700.0,ng/ml,57.4-68,"PO, oral;",247554.07
DDPD01015,Sulfamethoxazole,CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1,253.278,37100.0,ng/ml,37.1,"Oral single dose; adults; normal,healthy;",146479.36
DDPD01016,Glyburide,COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1,494.004,263.0,ng/ml,211-315,"PO, oral; Geriatric;",532.38
DDPD01016,Glyburide,COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1,494.004,223.0,ng/ml,144-302,"PO, oral; adults; patients;",451.41
DDPD01016,Glyburide,COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1,494.004,106.0,ng/ml,106.0,"Tablet, PO, oral; Drug form; adults; normal,healthy;",214.57
DDPD01016,Glyburide,COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1,494.004,104.0,ng/ml,104.0,"Tablet, PO, oral; Drug form; adults; normal,healthy;",210.52
DDPD01017,Minocycline,[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2,457.4764,1600.0,ng/ml,1.6±0.9,"PO, oral;",3497.45
DDPD01017,Minocycline,[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2,457.4764,3100.0,ng/ml,3.1,"PO, oral;",6776.31
DDPD01018,Guanfacine,NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl,246.093,2.5,ng/ml,2.5±0.6,"PO, oral; immediate release formulation;",10.16
DDPD01018,Guanfacine,NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl,246.093,1.0,ng/ml,1.0±0.3,"PO, oral; extended release formulation;",4.06
DDPD01018,Guanfacine,NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl,246.093,3.58,ng/ml,3.58±1.39,"PO, oral; adults; extended release formulation;",14.55
DDPD01018,Guanfacine,NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl,246.093,2.6,ng/ml,2.6±1.03,"PO, oral; Children; extended release formulation;",10.57
DDPD01018,Guanfacine,NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl,246.093,1.7,ng/ml,1.7±0.43,"PO, oral; Adolescents; extended release formulation;",6.91
DDPD01020,Isosorbide mononitrate,[H][C@]12OC[C@@H](O[N+]([O-])=O)[C@@]1([H])OC[C@@H]2O,191.1388,230.0355458,ng/ml,314-2093,"PO, oral;",1203.50
DDPD01023,Felodipine,CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC,384.254,13.064636,ng/ml,34±26,"PO, oral; immediate release formulation; normal,healthy;",34.00
DDPD01023,Felodipine,CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC,384.254,3.4967114,ng/ml,9.1±7.3,"PO, oral; extended release formulation; normal,healthy;",9.10
DDPD01024,Mycophenolic acid,COC1=C(C\C=C(/C)CCC(O)=O)C(O)=C2C(=O)OCC2=C1C,320.3371,13500.0,ng/ml,8-19,"PO, oral; Active metabolite; organ transplants;",42143.10
DDPD01026,Ketoconazole,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1,531.431,3050.0,ng/ml,2.5-3.6,Oral single dose;,5739.22
DDPD01026,Ketoconazole,CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1,531.431,1700579.2,ng/ml,3.2(1.4-4.5),"PO, oral; superficial mycotic infection;",3200000.00
DDPD01029,Irbesartan,CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1,428.5294,1900.0,ng/ml,1.9±0.4,Oral single dose;,4433.77
DDPD01029,Irbesartan,CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1,428.5294,2900.0,ng/ml,2.9±0.9,Oral single dose;,6767.33
DDPD01029,Irbesartan,CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1,428.5294,4900.0,ng/ml,4.9±1.2,Oral single dose;,11434.45
DDPD01029,Irbesartan,CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1,428.5294,5300.0,ng/ml,5.3±1.9,Oral single dose;,12367.88
DDPD01029,Irbesartan,CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1,428.5294,2040.0,ng/ml,2.04±0.4,Oral multiple dose;,4760.47
DDPD01029,Irbesartan,CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1,428.5294,3300.0,ng/ml,3.3±0.8,Oral multiple dose;,7700.76
DDPD01029,Irbesartan,CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1,428.5294,4400.0,ng/ml,4.4±0.7,Oral multiple dose;,10267.67
DDPD01029,Irbesartan,CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1,428.5294,5600.0,ng/ml,5.6±2.1,Oral multiple dose;,13067.95
DDPD01029,Irbesartan,CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1,428.5294,1300.0,ng/ml,1.3±0.4,"Male, men; normal,healthy;",3033.63
DDPD01030,Topotecan,CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O,421.4458,5.9,ng/ml,5.9±0.8,Oral single dose; Derivative; adults; solid tumors;,14.00
DDPD01030,Topotecan,CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O,421.4458,7.5,ng/ml,7.5±2.6,Oral single dose; Derivative; adults; solid tumors;,17.80
DDPD01030,Topotecan,CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O,421.4458,38.0,ng/ml,38±8,Derivative; adults; solid tumors;,90.17
DDPD01030,Topotecan,CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O,421.4458,19.0,ng/ml,19±2,Derivative; adults; solid tumors;,45.08
DDPD01033,Mercaptopurine,S=C1N=CNC2=C1NC=N2,152.177,112610.98,ng/ml,0.74±0.28,combination drug use; Children; tumor;,740000.00
DDPD01033,Mercaptopurine,S=C1N=CNC2=C1NC=N2,152.177,563054.9,ng/ml,3.7±0.6,combination drug use; Children; tumor;,3700000.00
DDPD01033,Mercaptopurine,S=C1N=CNC2=C1NC=N2,152.177,1050021.3,ng/ml,6.9,Children; tumor;,6900000.00
DDPD01035,Procainamide,CCN(CC)CCNC(=O)C1=CC=C(N)C=C1,235.3253,2200.0,ng/ml,2.2,"PO, oral; Male, men; adults;",9348.76
DDPD01035,Procainamide,CCN(CC)CCNC(=O)C1=CC=C(N)C=C1,235.3253,2900.0,ng/ml,2.9,"PO, oral;  Female, women; adults;",12323.37
DDPD01036,Tolterodine,CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(O)C=CC(C)=C1)C(C)C,325.4876,5.2,ng/ml,5.2±5.7,"PO, oral; Male, men; adults; normal,healthy; extensive metabolizers, EM;",15.98
DDPD01036,Tolterodine,CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(O)C=CC(C)=C1)C(C)C,325.4876,38.0,ng/ml,38±15,"PO, oral; Male, men; adults; normal,healthy; poor metabolizers, PM;",116.75
DDPD01037,Selegiline,C[C@H](CC1=CC=CC=C1)N(C)CC#C,187.286,1.1,ng/ml,1.1±0.4,"PO, oral; adults;",5.87
DDPD01037,Selegiline,C[C@H](CC1=CC=CC=C1)N(C)CC#C,187.286,15.0,ng/ml,~15,"PO, oral; Active metabolite; adults;",80.09
DDPD01039,Fenofibrate,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1,360.831,7750.0,ng/ml,6-9.5,"PO, oral; normal,healthy; fasting;",21478.20
DDPD01039,Fenofibrate,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1,360.831,8600.0,ng/ml,8.6±0.9,"Tablet, PO, oral; immediate release formulation;",23833.87
DDPD01039,Fenofibrate,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1,360.831,10800.0,ng/ml,10.8±0.6,"Capsule, PO, Oral; Drug form;",29930.91
DDPD01041,Thalidomide,O=C1N(C2CCC(=O)NC2=O)C(=O)C2=CC=CC=C12,258.2295,2000.0,ng/ml,2.0±0.6,"Oral single dose; Male, men; normal,healthy;",7745.05
DDPD01042,Melphalan,N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O,305.2,310.0,ng/ml,0.31±0.15,"PO, oral; tumor;",1015.73
DDPD01042,Melphalan,N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O,305.2,1300.0,ng/ml,1.3±0.95,"intravenous injection, IV; tumor;",4259.50
DDPD01045,Rifampicin,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C,822.9402,6500.0,ng/ml,6.5±3.5,"PO, oral; tuberculosis;",7898.51
DDPD01047,Fluocinonide,[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)COC(C)=O,494.5249,3000.0,ng/ml,3.0±0.89,"Tablet, PO, oral;",6066.43
DDPD01050,Ibuprofen,CC(C)CC1=CC=C(C=C1)C(C)C(O)=O,206.2808,20000.0,ng,20,"PO, oral;",96955.22
DDPD01050,Ibuprofen,CC(C)CC1=CC=C(C=C1)C(C)C(O)=O,206.2808,61100.0,ng/ml,61.1±5.5,Oral single dose; Raceme D/L;,296198.19
DDPD01053,Benzylpenicillin,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O,334.39,740.0,ng/ml,0.28-1.2,Liquid;,2212.98
DDPD01053,Benzylpenicillin,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O,334.39,12000.0,ng/ml,12.0,"IM,intramuscular injection; Derivative;",35886.24
DDPD01053,Benzylpenicillin,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O,334.39,940.0,ng/ml,0.94,"IM,intramuscular injection; Derivative;",2811.09
DDPD01053,Benzylpenicillin,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O,334.39,160.0,ng/ml,0.16,"IM,intramuscular injection; Derivative;",478.48
DDPD01058,Praziquantel,O=C(C1CCCCC1)N1CC2N(CCC3=CC=CC=C23)C(=O)C1,312.4061,3550.0,ng/ml,0.8-6.3,Oral single dose;,11363.41
DDPD01060,Amoxicillin,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O,365.404,3930.0,ng/ml,3.93±1.13,"PO, oral;",10755.22
DDPD01060,Amoxicillin,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O,365.404,11210.0,ng/ml,11.21±3.42,"PO, oral;",30678.37
DDPD01060,Amoxicillin,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O,365.404,46000.0,ng/ml,46±12,"intravenous injection, IV; Elderly; normal,healthy;",125888.06
DDPD01060,Amoxicillin,[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O,365.404,5000.0,ng/ml,5.0,Oral single dose; adults;,13683.48
DDPD01062,Oxybutynin,CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1,357.4864,8.2,ng/ml,8.2,"PO, oral;",22.94
DDPD01062,Oxybutynin,CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1,357.4864,69.7,ng/ml,41-98.4,"PO, oral; Active metabolite;",194.97
DDPD01062,Oxybutynin,CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1,357.4864,12.4,ng/ml,12.4±4.1,"PO, oral; immediate release formulation;",34.69
DDPD01062,Oxybutynin,CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1,357.4864,4.2,ng/ml,4.2±1.6,"PO, oral; extended release formulation;",11.75
DDPD01067,Glipizide,CC1=NC=C(N=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1,445.535,465.0,ng/ml,465±139,"PO, oral; immediate release formulation; young; normal,healthy;",1043.69
DDPD01068,Clonazepam,[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,315.711,17.0,ng/ml,17±5.4,"Tablet, PO, oral; adults; normal,healthy;",53.85
DDPD01068,Clonazepam,[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C2=CC=CC=C2Cl)C=C1,315.711,16.0,ng/ml,3-29,"intravenous injection, IV; adults; normal,healthy;",50.68
DDPD01069,Promethazine,CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C,284.419,22.0,ng/ml,22,"IM,intramuscular injection;",77.35
DDPD01069,Promethazine,CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C,284.419,10.0,ng/ml,10,"intravenous injection, IV;",35.16
DDPD01069,Promethazine,CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C,284.419,10.2,ng/ml,2.4-18.0,"PO, oral;",35.86
DDPD01072,Atazanavir,COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=CC=CC=N1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C,704.8555,5400.0,ng/ml,5.4±1.4,"PO, oral; food;",7661.14
DDPD01073,Fludarabine,NC1=NC(F)=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,285.235,570.0,ng/ml,0.57,adults; tumor;,1998.35
DDPD01075,Diphenhydramine,CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1,255.3547,66.0,ng/ml,66±22,"Oral single dose; fasting; adults; normal,healthy;",258.46
DDPD01075,Diphenhydramine,CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1,255.3547,230.0,ng/ml,~230,"fasting; adults; normal,healthy;",900.71
DDPD01076,Atorvastatin,CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1,558.6398,28.0,ng/ml,28,"PO, oral;",50.12
DDPD01076,Atorvastatin,CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1,558.6398,14.9,ngEq/ml,14.9±1.8,"PO, oral; normal,healthy;",26.67
DDPD01079,Tegaserod,CCCCCNC(=N)N\N=C\C1=CNC2=C1C=C(OC)C=C2,301.394,2.7,ng/ml,2.7±1.2,"PO, oral;",8.96
DDPD01097,Leflunomide,CC1=C(C=NO1)C(=O)NC1=CC=C(C=C1)C(F)(F)F,270.2073,35000.0,ng/ml,35.0,"PO, oral; rheumatoid arthritis;",129530.18
DDPD01098,Rosuvastatin,CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O,481.538,6.06,ng/ml,6.06,"PO, oral; normal,healthy;",12.58
DDPD01098,Rosuvastatin,CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O,481.538,4.6,ng/ml,4.6±2.1,"PO, oral;",9.55
DDPD01101,Capecitabine,CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O,359.3501,6600.0,ng/ml,6.6±6.0,"PO, oral;",18366.49
DDPD01101,Capecitabine,CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O,359.3501,470.0,ng/ml,0.47±0.47,"PO, oral; Components;",1307.92
DDPD01104,Sertraline,CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12,306.23,37.5,ng/ml,20-55,"PO, oral;",122.46
DDPD01104,Sertraline,CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12,306.23,118.0,ng/ml,118±22,"PO, oral; Male, men; adults; normal,healthy;",385.33
DDPD01104,Sertraline,CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12,306.23,166.0,ng/ml,166±65,"PO, oral;  Female, women; adults; normal,healthy;",542.08
DDPD01109,Heparin,CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O,N.A.,70.0,ng/ml,70±39,,
DDPD01110,Miconazole,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1,416.129,15100.0,ng/ml,15.1±16.2,"Tablet, PO, oral; normal,healthy;",36286.82
DDPD01110,Miconazole,ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1,416.129,10.71,ng/ml,10.71,Vaginal Administration;,25.74
DDPD01112,Cefuroxime,[H][C@]12SCC(COC(N)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CC=CO1)C(O)=O,424.385,8500.0,ng/ml,7-10,"Oral single dose; adults; normal,healthy;",20028.98
DDPD01114,Chlorpheniramine,CN(C)CCC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1,274.788,43.5,ng/ml,16-71,"PO, oral; immediate release formulation; adults; normal,healthy;",158.30
DDPD01114,Chlorpheniramine,CN(C)CCC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1,274.788,46.5,ng/ml,17-76,"PO, oral; Sustained Release formulation; adults; normal,healthy;",169.22
DDPD01115,Nifedipine,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC,346.3346,10.0,ng/ml,10,sublingual;,28.87
DDPD01115,Nifedipine,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC,346.3346,82.0,ng/ml,82,"PO, oral;",236.77
DDPD01115,Nifedipine,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC,346.3346,79.0,ng/ml,79±44,"Capsule, PO, Oral; immediate release formulation; Male, men; adults; normal,healthy;",228.10
DDPD01115,Nifedipine,COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC,346.3346,42.0,ng/ml,35-49,"PO, oral; extended release formulation; Male, men; adults; normal,healthy;",121.27
DDPD01118,Amiodarone,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2,645.3116,1950.0,ng/ml,1.5-2.4,"PO, oral; adults; patients;",3021.80
DDPD01124,Tolbutamide,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1,270.348,53000.0,ng/ml,53±12,Oral single dose;,196043.62
DDPD01128,Bicalutamide,CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC1=CC(=C(C=C1)C#N)C(F)(F)F,430.373,734.0,ng/ml,734.0,"Oral single dose; Optical rotation R; Male, men; normal,healthy;",1705.50
DDPD01128,Bicalutamide,CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC1=CC(=C(C=C1)C#N)C(F)(F)F,430.373,84.0,ng/ml,84.0,"Oral single dose; Optical rotation S; Male, men; normal,healthy;",195.18
DDPD01128,Bicalutamide,CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC1=CC(=C(C=C1)C#N)C(F)(F)F,430.373,8900.0,ng/ml,8.9±3.5,"Oral multiple dose; Optical rotation R/S; Male, men; normal,healthy;",20679.74
DDPD01132,Pioglitazone,CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1,356.439,1600.0,ng/ml,1.6±0.2,"PO, oral;",4488.85
DDPD01132,Pioglitazone,CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1,356.439,400.0,ng/ml,0.4±0.2,"PO, oral; Active metabolite;",1122.21
DDPD01132,Pioglitazone,CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1,356.439,1400.0,ng/ml,1.4±0.5,"PO, oral; Active metabolite;",3927.74
DDPD01133,Tiludronic acid,OP(O)(=O)C(SC1=CC=C(Cl)C=C1)P(O)(O)=O,318.608,3350.0,ng/ml,3.35±1.07,"PO, oral;",10514.49
DDPD01136,Carvedilol,COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2,406.4742,192.0,ng/ml,122-262,"PO, oral;",472.35
DDPD01136,Carvedilol,COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2,406.4742,87.5,ng/ml,24-151,"PO, oral;",215.27
DDPD01136,Carvedilol,COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2,406.4742,63.5,ng/ml,58-69,,156.22
DDPD01136,Carvedilol,COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2,406.4742,105.0,ng/ml,105±12,"PO, oral; adults; normal,healthy;",258.32
DDPD01137,Levofloxacin,C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1,361.3675,6200.0,ng/ml,6.2±1.0,"PO, oral; intravenous injection, IV;",17157.05
DDPD01137,Levofloxacin,C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1,361.3675,11.5,ng/ml,11.5±4.0,"PO, oral; intravenous injection, IV;",31.82
DDPD01137,Levofloxacin,C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1,361.3675,4500.0,ng/ml,4.5±0.9,"Oral single dose; Male, men; adults; normal,healthy;",12452.70
DDPD01142,Doxepin,[H]C(CCN(C)C)=C1C2=CC=CC=C2COC2=CC=CC=C12,279.3761,27.3,ng/ml,8.8-45.8,"PO, oral;",97.72
DDPD01142,Doxepin,[H]C(CCN(C)C)=C1C2=CC=CC=C2COC2=CC=CC=C12,279.3761,28.0,ng/ml,28±11,"PO, oral; Derivative; depression;",100.22
DDPD01142,Doxepin,[H]C(CCN(C)C)=C1C2=CC=CC=C2COC2=CC=CC=C12,279.3761,39.0,ng/ml,39±19,"PO, oral; Derivative; depression;",139.60
DDPD01156,Bupropion,CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1,239.741,141.0,ng/ml,141±19,"Oral single dose; immediate release formulation; Male, men; adults; normal,healthy;",588.13
DDPD01156,Bupropion,CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1,239.741,142.0,ng/ml,142±28,"Oral single dose; Sustained Release formulation; Male, men; adults; normal,healthy;",592.31
DDPD01162,Terazosin,COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1CCCO1,387.4329,16.0,ng/ml,16.0,"Tablet, PO, oral; normal,healthy;",41.30
DDPD01167,Itraconazole,CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@H]2CO[C@@](CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1,705.633,649.0,ng/ml,649±289,"PO, oral; adults;",919.74
DDPD01174,Phenobarbital,CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1,232.2353,13100.0,ng/ml,13.1±4.5,"PO, oral; epilepsy;",56408.31
DDPD01175,Escitalopram,CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1,324.3919,21.0,ng/ml,21,"PO, oral; patients;",64.74
DDPD01175,Escitalopram,CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1,324.3919,63.0,ng/ml,63,"PO, oral; patients;",194.21
DDPD01177,Idarubicin,C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(CC2=C1C(O)=C1C(=O)C3=CC=CC=C3C(=O)C1=C2O)C(C)=O,497.4939,6.9,ng/ml,6.9±0.1,Oral single dose; tumor;,13.87
DDPD01177,Idarubicin,C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(CC2=C1C(O)=C1C(=O)C3=CC=CC=C3C(=O)C1=C2O)C(C)=O,497.4939,22.0,ng/ml,22±4,Oral single dose; Active metabolite; tumor;,44.22
DDPD01179,Podofilox,[H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(OC)C(OC)=C1)C1=CC3=C(OCO3)C=C1[C@@H]2O,414.4053,9.0,ng/ml,1-17,skin/dermal;,21.72
DDPD01181,Ifosfamide,ClCCNP1(=O)OCCCN1CCCl,261.086,52217200.0,ng/ml,200（163-245）,"PO, oral; Advanced tumors;",200000000.00
DDPD01181,Ifosfamide,ClCCNP1(=O)OCCCN1CCCl,261.086,53000458.0,ng/ml,203(168-232),"intravenous injection, IV; Advanced tumors;",203000000.00
DDPD01183,Naloxone,OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O,327.3743,0.88,ng/ml,0.88,"IM,intramuscular injection;",2.69
DDPD01183,Naloxone,OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O,327.3743,2.91,ng/ml,2.91,nasal spray;,8.89
DDPD01183,Naloxone,OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O,327.3743,4.83,ng/ml,4.83,nasal spray;,14.75
DDPD01183,Naloxone,OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O,327.3743,10.0,ng/ml,10±1,"adults; normal,healthy;",30.55
DDPD01190,Clindamycin,CCC[C@@H]1C[C@H](N(C)C1)C(=O)NC(C(C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O,424.983,2500.0,ng/ml,2.5,"PO, oral;",5882.59
DDPD01190,Clindamycin,CCC[C@@H]1C[C@H](N(C)C1)C(=O)NC(C(C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O,424.983,17200.0,ng/ml,17.2±3.5,"intravenous injection, IV; Male, men; adults; normal,healthy;",40472.21
DDPD01190,Clindamycin,CCC[C@@H]1C[C@H](N(C)C1)C(=O)NC(C(C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O,424.983,2500.0,ng/ml,2.5,"PO, oral; adults;",5882.59
DDPD01195,Flecainide,FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1,414.3427,458.0,ng/ml,458±100,"PO, oral; adults; normal,healthy;",1105.37
DDPD01202,Levetiracetam,CC[C@H](N1CCCC1=O)C(N)=O,170.212,31000.0,ng/ml,31,Oral single dose;,182125.82
DDPD01202,Levetiracetam,CC[C@H](N1CCCC1=O)C(N)=O,170.212,43000.0,ng/ml,43,Oral multiple dose;,252626.14
DDPD01202,Levetiracetam,CC[C@H](N1CCCC1=O)C(N)=O,170.212,24800.0,ng/ml,24.8,Oral single dose; food;,145700.66
DDPD01202,Levetiracetam,CC[C@H](N1CCCC1=O)C(N)=O,170.212,10000.0,ng/ml,~10,"PO, oral; adults; normal,healthy;",58750.26
DDPD01203,Nadolol,CC(C)(C)NCC(O)COC1=CC=CC2=C1C[C@H](O)[C@H](O)C2,309.4006,69.0,ng/ml,69±15,Oral single dose;,223.01
DDPD01203,Nadolol,CC(C)(C)NCC(O)COC1=CC=CC2=C1C[C@H](O)[C@H](O)C2,309.4006,132.0,ng/ml,132±27,,426.63
DDPD01204,Mitoxantrone,OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(C(O)=CC=C1O)C2=O,444.4809,308.0,ng/ml,308±133,,692.94
DDPD01205,Flumazenil,CCOC(=O)C1=C2CN(C)C(=O)C3=C(C=CC(F)=C3)N2C=N1,303.2884,15.0,ng/ml,10-20,"intravenous injection, IV;",49.46
DDPD01211,Clarithromycin,[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC,747.9534,2400.0,ng/ml,2.4,"PO, oral; adults; normal,healthy;",3208.76
DDPD01211,Clarithromycin,[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC,747.9534,700.0,ng/ml,0.7,"PO, oral; Derivative; adults; normal,healthy;",935.89
DDPD01216,Finasteride,[H][C@@]12CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])NC(=O)C=C[C@]12C,372.5441,37.0,ng/ml,37(27-49),"PO, oral;",99.32
DDPD01216,Finasteride,[H][C@@]12CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])NC(=O)C=C[C@]12C,372.5441,37.0,ng/ml,37(27-49),"Oral single dose; adults; normal,healthy;",99.32
DDPD01217,Anastrozole,CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N,293.3663,46.0,ng/ml,46.0,"Oral single dose; postmenopausal women;  Female, women;",156.80
DDPD01221,Ketamine,CNC1(CCCCC1=O)C1=CC=CC=C1Cl,237.725,750.0,ng/ml,0.75,,3154.91
DDPD01222,Budesonide,[H][C@@]12C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,430.5339,1.5,ng/ml,1.50±0.79,"PO, oral;",3.48
DDPD01222,Budesonide,[H][C@@]12C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,430.5339,0.47358729,ng/ml,0.6-1.6,"inhalation, IH;",1.10
DDPD01222,Budesonide,[H][C@@]12C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,430.5339,1.11938814,ng/ml,2.6,"inhalation, IH;",2.60
DDPD01222,Budesonide,[H][C@@]12C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,430.5339,1.35,ng/ml,1.35±0.96,"Tablet, PO, oral; extended release formulation; different study;",3.14
DDPD01224,Quetiapine,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12,383.507,467.0,ng/ml,467,"PO, oral; extended release formulation;",1217.71
DDPD01224,Quetiapine,OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12,383.507,278.0,ng/ml,278.0,"PO, oral; schizophrenia;",724.89
DDPD01229,Paclitaxel,[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C,853.9061,195.0,ng/ml,195,"intravenous infusion, IV in drop;",228.36
DDPD01229,Paclitaxel,[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C,853.9061,725820.185,ng/ml,0.85±0.21,"intravenous infusion, IV in drop; adults; tumor;",850000.00
DDPD01233,Metoclopramide,CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC,299.796,41.0,ng/ml,41.0,"inhalation, IH;",136.76
DDPD01233,Metoclopramide,CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC,299.796,80.0,ng/ml,80.0,Oral single dose; Elderly;,266.85
DDPD01233,Metoclopramide,CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC,299.796,18.0,ng/ml,18±6.2,Oral single dose; Infants;,60.04
DDPD01234,Dexamethasone,[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,392.4611,34.6,ng/ml,34.6±6.0,"IM,intramuscular injection;",88.16
DDPD01234,Dexamethasone,[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,392.4611,13.9,ng/ml,13.9±6.8,"PO, oral;",35.42
DDPD01235,Levodopa,N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O,197.1879,1700.0,ng/ml,1.7±0.8,combination drug use; young;,8621.22
DDPD01235,Levodopa,N[C@@H](CC1=CC(O)=C(O)C=C1)C(O)=O,197.1879,1900.0,ng/ml,1.9±0.6,combination drug use; Elderly;,9635.48
DDPD01238,Aripiprazole,ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl,448.385,242.0,ng/ml,242±36,"PO, oral;",539.71
DDPD01241,Gemfibrozil,CC1=CC(OCCCC(C)(C)C(O)=O)=C(C)C=C1,250.3334,46000.0,ng/ml,46±16,"PO, oral; normal,healthy;",183754.94
DDPD01241,Gemfibrozil,CC1=CC(OCCCC(C)(C)C(O)=O)=C(C)C=C1,250.3334,13800.0,ng/ml,13.8±11.1,"PO, oral;",55126.48
DDPD01241,Gemfibrozil,CC1=CC(OCCCC(C)(C)C(O)=O)=C(C)C=C1,250.3334,23000.0,ng/ml,23.0±10.3,"PO, oral; hepatopathy，LD;",91877.47
DDPD01241,Gemfibrozil,CC1=CC(OCCCC(C)(C)C(O)=O)=C(C)C=C1,250.3334,20000.0,ng/ml,15-25,"PO, oral;",79893.45
DDPD01242,Clomipramine,CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=C(Cl)C=C2,314.852,92000000.0,ng/ml,92(56-154),Oral single dose;,292200780.05
DDPD01248,Docetaxel,[H][C@@]1(C[C@@]2(O)[C@@H](OC(=O)C3=CC=CC=C3)[C@]3([H])[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C(=C1C)C2(C)C)OC(C)=O)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1,807.8792,2400.0,ng/ml,2.4±0.9,"intravenous infusion, IV in drop; tumor;",2970.74
DDPD01275,Hydralazine,NNC1=NN=CC2=CC=CC=C12,160.1759,114.5257685,mg/ml,0.12-1.31,"PO, oral; patients;",715.00
DDPD01327,Cefazolin,[H][C@]12SCC(CSC3=NN=C(C)S3)=C(N1C(=O)[C@H]2NC(=O)CN1C=NN=N1)C(O)=O,454.507,42000.0,ng/ml,42±9.5,,92407.82
DDPD01327,Cefazolin,[H][C@]12SCC(CSC3=NN=C(C)S3)=C(N1C(=O)[C@H]2NC(=O)CN1C=NN=N1)C(O)=O,454.507,237000.0,ng/ml,237±285,,521444.11
DDPD01330,Cefotetan,[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)C1SC(S1)=C(C(N)=O)C(O)=O)OC)C(O)=O,575.619,91000.0,ng/ml,91.0,"adults; normal,healthy;",158090.68
DDPD01330,Cefotetan,[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)C1SC(S1)=C(C(N)=O)C(O)=O)OC)C(O)=O,575.619,413500.0,ng/ml,336-491,"adults; normal,healthy;",718357.11
DDPD01330,Cefotetan,[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)C1SC(S1)=C(C(N)=O)C(O)=O)OC)C(O)=O,575.619,38000.0,ng/ml,38.0,"adults; normal,healthy;",66015.89
DDPD01337,Pancuronium,[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1,572.8619,670.0,ng/ml,0.67,"intravenous injection, IV; surgery;",1169.57
DDPD01339,Vecuronium,[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1,557.8274,130.0,ng/ml,130±20,,233.05
DDPD01364,Ephedrine,CN[C@@H](C)[C@H](O)C1=CC=CC=C1,165.2322,79.5,ng/ml,79.5,"PO, oral;",481.14
DDPD01394,Colchicine,COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O,399.437,2.5,ng/ml,2.5,"PO, oral;",6.26
DDPD01395,Drospirenone,[H][C@@]12C[C@]1([H])[C@@]1([H])[C@]3([H])[C@]4([H])C[C@]4([H])[C@@]4(CCC(=O)O4)[C@@]3(C)CC[C@]1([H])[C@@]1(C)CCC(=O)C=C21,366.4932,73.5,ng/ml,60-87,,200.55
DDPD01395,Drospirenone,[H][C@@]12C[C@]1([H])[C@@]1([H])[C@]3([H])[C@]4([H])C[C@]4([H])[C@@]4(CCC(=O)O4)[C@@]3(C)CC[C@]1([H])[C@@]1(C)CCC(=O)C=C21,366.4932,21.9,ng/ml,21.9,combination drug use;,59.76
DDPD01400,Neostigmine,CN(C)C(=O)OC1=CC(=CC=C1)[N+](C)(C)C,223.2915,275.0,ng/ml,200-350,patients;,1231.57
DDPD01413,Cefepime,CO\N=C(/C(=O)N[C@@H]1C(=O)N2[C@]1([H])SCC(C[N+]1(C)CCCC1)=C2C([O-])=O)C1=CSC(N)=N1,480.561,65000.0,ng/ml,65±7,"intravenous injection, IV;",135258.58
DDPD01438,Phenazopyridine,NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1,213.2385,65.0,ng/ml,65.00±29.23,,304.82
DDPD01551,Dihydrocodeine,[H][C@@]12OC3=C4C(C[C@H]5N(C)CC[C@@]14[C@@]5([H])CC[C@@H]2O)=CC=C3OC,301.3801,71.8,ng/ml,71.8,"intravenous injection, IV;",238.24
DDPD01551,Dihydrocodeine,[H][C@@]12OC3=C4C(C[C@H]5N(C)CC[C@@]14[C@@]5([H])CC[C@@H]2O)=CC=C3OC,301.3801,146.0,ng/ml,146,"PO, oral;",484.44
DDPD01576,Dextroamphetamine,C[C@H](N)CC1=CC=CC=C1,135.2062,61.0,ng/ml,61±20,"PO, oral; Raceme D; extended release formulation;",451.16
DDPD01591,Solifenacin,O=C(O[C@H]1CN2CCC1CC2)N1CCC2=CC=CC=C2[C@@H]1C1=CC=CC=C1,362.473,32.3,ng/ml,32.3,"PO, oral;",89.11
DDPD01591,Solifenacin,O=C(O[C@H]1CN2CCC1CC2)N1CCC2=CC=CC=C2[C@@H]1C1=CC=CC=C1,362.473,62.9,ng/ml,62.9,"PO, oral;",173.53
DDPD01597,Cilastatin,CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O,358.453,10100.0,ng/ml,8.2-12,"IM,intramuscular injection;",28176.64
DDPD01597,Cilastatin,CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O,358.453,65000.0,ng/ml,60-70,"intravenous infusion, IV in drop;",181334.79
DDPD01598,Imipenem,[H][C@]12CC(SCC\N=C\N)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O,299.346,10100.0,ng/ml,8.2-12,"IM,intramuscular injection;",33740.22
DDPD01598,Imipenem,[H][C@]12CC(SCC\N=C\N)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O,299.346,65000.0,ng/ml,60-70,"intravenous infusion, IV in drop;",217140.03
DDPD01601,Lopinavir,CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1,628.8008,10800.0,ng/ml,9.8±3.7-11.8±3.7,combination drug use;,17175.55
DDPD01601,Lopinavir,CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1,628.8008,9800.0,ng/ml,9.8±3.7,combination drug use;,15585.22
DDPD01606,Tazobactam,[H][C@@]12CC(=O)N1[C@@H](C(O)=O)[C@](C)(CN1C=CN=N1)S2(=O)=O,300.291,18200.0,ng/ml,18-18.4,combination drug use;,60607.88
DDPD01610,Valganciclovir,CC(C)[C@H](N)C(=O)OCC(CO)OCN1C=NC2=C1NC(N)=NC2=O,354.3617,200.0,ng/ml,0.20±0.7,"PO, oral; food;",564.40
DDPD01610,Valganciclovir,CC(C)[C@H](N)C(=O)OCC(CO)OCN1C=NC2=C1NC(N)=NC2=O,354.3617,5600.0,ng/ml,5.6±1.5,"PO, oral; Drug form; food;",15803.06
DDPD01611,Hydroxychloroquine,CCN(CCO)CCCC(C)NC1=C2C=CC(Cl)=CC2=NC=C1,335.872,50.3,ng/ml,50.3,"PO, oral;",149.76
DDPD01611,Hydroxychloroquine,CCN(CCO)CCCC(C)NC1=C2C=CC(Cl)=CC2=NC=C1,335.872,1918.0,ng/ml,1918(1161-2436),"intravenous injection, IV;",5710.51
DDPD01611,Hydroxychloroquine,CCN(CCO)CCCC(C)NC1=C2C=CC(Cl)=CC2=NC=C1,335.872,1918.0,ng/ml,1918(1161-2436),"intravenous injection, IV;",5710.51
DDPD01620,Pheniramine,CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=N1,240.3434,0.2335,ng/ml,173-294,,0.97
DDPD01956,Taurine,NCCS(O)(=O)=O,125.147,8850.0,ng/ml,2-15.7,"PO, oral;",70716.84
DDPD01956,Taurine,NCCS(O)(=O)=O,125.147,85800.0,ng/ml,59-112.6,"normal,healthy;",685593.74
DDPD04844,Tetrabenazine,COC1=C(OC)C=C2C3CC(=O)C(CC(C)C)CN3CCC2=C1,317.4226,4.8,ng/ml,4.8,"PO, oral; Huntington's disease; tardive dyskinesia;",15.12
DDPD04861,Nebivolol,OC(CNCC(O)C1CCC2=C(O1)C=CC(F)=C2)C1CCC2=C(O1)C=CC(F)=C2,405.435,2.75,ng/ml,2.75±1.55,Raceme D;,6.78
DDPD04861,Nebivolol,OC(CNCC(O)C1CCC2=C(O1)C=CC(F)=C2)C1CCC2=C(O1)C=CC(F)=C2,405.435,5.29,ng/ml,5.29±2.06,Raceme L;,13.05
DDPD04861,Nebivolol,OC(CNCC(O)C1CCC2=C(O1)C=CC(F)=C2)C1CCC2=C(O1)C=CC(F)=C2,405.435,8.02,ng/ml,8.02±3.47,Raceme D/L;,19.78
DDPD04861,Nebivolol,OC(CNCC(O)C1CCC2=C(O1)C=CC(F)=C2)C1CCC2=C(O1)C=CC(F)=C2,405.435,68.34,ng/ml,68.34±44.68,Derivative;,168.56
DDPD04890,Bepotastine,OC(=O)CCCN1CCC(CC1)OC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1,388.888,7.3,ng/ml,7.3±1.9,,18.77
DDPD04896,Milnacipran,CCN(CC)C(=O)C1(CC1CN)C1=CC=CC=C1,246.354,341.0,ng/ml,341,"PO, oral; Raceme L;",1384.19
DDPD04911,Oritavancin,CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(NCC5=CC=C(C=C5)C5=CC=C(Cl)C=C5)[C@@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O[C@H]1C[C@](C)(N)[C@@H](O)[C@H](C)O1)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2,1793.101,138000.0,ng/ml,138,,76961.64
DDPD04911,Oritavancin,CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(NCC5=CC=C(C=C5)C5=CC=C(Cl)C=C5)[C@@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O[C@H]1C[C@](C)(N)[C@@H](O)[C@H](C)O1)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2,1793.101,6150.0,ng/ml,4.7-7.6,different study;,3429.81
DDPD04931,Afamelanotide,CCCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(N)=O,1646.8452,3.7,ng/ml,3.7±1.3,,2.25
DDPD04938,Ospemifene,OCCOC1=CC=C(C=C1)C(=C(\CCCl)C1=CC=CC=C1)\C1=CC=CC=C1,378.891,533.0,ng/ml,533,Oral single dose; postmenopausal women; fasting;,1406.74
DDPD04938,Ospemifene,OCCOC1=CC=C(C=C1)C(=C(\CCCl)C1=CC=CC=C1)\C1=CC=CC=C1,378.891,1198.0,ng/ml,1198,Oral single dose; postmenopausal women; food;,3161.86
DDPD04948,Lofexidine,CC(OC1=C(Cl)C=CC=C1Cl)C1=NCCN1,259.132,1.26,ng/ml,1.26,"PO, oral;",4.86
DDPD05154,Pretomanid,[O-][N+](=O)C1=CN2C[C@@H](COC2=N1)OCC1=CC=C(OC(F)(F)F)C=C1,359.2574,1700.0,ng/ml,1.7,Oral single dose;,4731.98
DDPD05154,Pretomanid,[O-][N+](=O)C1=CN2C[C@@H](COC2=N1)OCC1=CC=C(OC(F)(F)F)C=C1,359.2574,1100.0,ng/ml,1.1,Oral single dose; different study;,3061.87
DDPD05351,Dexlansoprazole,CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1,369.36,688.0,ng/ml,688,"PO, oral;",1862.68
DDPD05676,Apremilast,CCOC1=CC(=CC=C1OC)[C@@H](CS(C)(=O)=O)N1C(=O)C2=CC=CC(NC(C)=O)=C2C1=O,460.5,584.0,ng/ml,584,"PO, oral;",1268.19
DDPD05990,Obeticholic acid,[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)[C@H](CC)[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O,420.6252,41.25,ng/ml,28.8-53.7,"PO, oral;",98.07
DDPD06196,Icatibant,[H][C@]12C[C@]([H])(N(C(=O)[C@@]3([H])CC4=C(CN3C(=O)[C@H](CO)NC(=O)[C@H](CC3=CC=CS3)NC(=O)CNC(=O)[C@]3([H])C[C@@H](O)CN3C(=O)[C@@H]3CCCN3C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](N)CCCNC(N)=N)C=CC=C4)[C@@]1([H])CCCC2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O,1304.54,974.0,ng/ml,974±280,"subcutaneous injection, SC;",746.62
DDPD06201,Rufinamide,NC(=O)C1=CN(CC2=C(F)C=CC=C2F)N=N1,238.1935,4010.0,ng/ml,4.01,"PO, oral;",16835.05
DDPD06201,Rufinamide,NC(=O)C1=CN(CC2=C(F)C=CC=C2F)N=N1,238.1935,8680.0,ng/ml,8.68,"PO, oral;",36440.96
DDPD06204,Tapentadol,CC[C@H]([C@@H](C)CN(C)C)C1=CC(O)=CC=C1,221.3385,64.2,ng/ml,64.2,"PO, oral; immediate release formulation;",290.05
DDPD06204,Tapentadol,CC[C@H]([C@@H](C)CN(C)C)C1=CC(O)=CC=C1,221.3385,22.5,ng/ml,22.5,"PO, oral; extended release formulation;",101.65
DDPD06207,Silodosin,C[C@H](CC1=CC2=C(N(CCCO)CC2)C(=C1)C(N)=O)NCCOC1=CC=CC=C1OCC(F)(F)F,495.5345,61.6,ng/ml,61.6±27.54,"PO, oral; food;",124.31
DDPD06212,Tolvaptan,CC1=CC=CC=C1C(=O)NC1=CC(C)=C(C=C1)C(=O)N1CCC[C@@H](O)C2=C1C=CC(Cl)=C2,448.941,374.0,ng/ml,374,,833.07
DDPD06212,Tolvaptan,CC1=CC=CC=C1C(=O)NC1=CC(C)=C(C=C1)C(=O)N1CCC[C@@H](O)C2=C1C=CC(Cl)=C2,448.941,418.0,ng/ml,418,,931.08
DDPD06212,Tolvaptan,CC1=CC=CC=C1C(=O)NC1=CC(C)=C(C=C1)C(=O)N1CCC[C@@H](O)C2=C1C=CC(Cl)=C2,448.941,460.0,ng/ml,460,heart failure;,1024.63
DDPD06212,Tolvaptan,CC1=CC=CC=C1C(=O)NC1=CC(C)=C(C=C1)C(=O)N1CCC[C@@H](O)C2=C1C=CC(Cl)=C2,448.941,723.0,ng/ml,723,heart failure;,1610.46
DDPD06213,Regadenoson,CNC(=O)C1=CN(N=C1)C1=NC2=C(N=CN2[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C(N)=N1,390.354,12.3,ng/ml,12.3,"intravenous injection, IV;",31.51
DDPD06216,Asenapine,OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1,401.84,4.0,ng/ml,4,,9.95
DDPD06217,Vernakalant,COC1=C(OC)C=C(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)C=C1,349.471,3900.0,ng/ml,3.9,patients;,11159.72
DDPD06217,Vernakalant,COC1=C(OC)C=C(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)C=C1,349.471,4300.0,ng/ml,4.3,patients;,12304.31
DDPD06230,Nalmefene,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]1(O)CCC2=C,339.435,16.5,ng/ml,16.5,Oral single dose;,48.61
DDPD06230,Nalmefene,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]1(O)CCC2=C,339.435,23.1,ng/ml,21.45-24.75,"PO, oral; high-fat meal;",68.05
DDPD06230,Nalmefene,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]1(O)CCC2=C,339.435,24.0,ng/ml,24±11,"Oral single dose; Male, men; normal,healthy;",70.71
DDPD06230,Nalmefene,[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]1(O)CCC2=C,339.435,17.0,ng/ml,17±6.3,"Male, men; normal,healthy;",50.08
DDPD06282,Levocetirizine,OC(=O)COCCN1CCN(CC1)[C@H](C1=CC=CC=C1)C1=CC=C(Cl)C=C1,388.89,27000.0,ng/ml,27±0.04,"PO, oral;",69428.37
DDPD06283,Ziconotide,CC1C(=O)NC(C(=O)NC2CSSCC3C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(CSSCC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NCC(=O)N1)CCCCN)CCCCN)N)C(=O)NC(C(=O)NCC(=O)NC(C(=O)N3)CO)C(C)O)NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC2=O)CO)CCCNC(=N)N)CC(C)C)CCSC)CC4=CC=C(C=C4)O)CC(=O)O)C(=O)N)CCCCN)CO)CCCNC(=N)N)CCCCN,N.A.,74.2,ng/ml,16.4-132,intrathecal administration;,
DDPD06335,Saxagliptin,[H][C@@]12C[C@]1([H])N([C@@H](C2)C#N)C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,315.41,24.0,ng/ml,24,"Oral single dose; normal,healthy;",76.09
DDPD06335,Saxagliptin,[H][C@@]12C[C@]1([H])N([C@@H](C2)C#N)C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,315.41,47.0,ng/ml,47,"Oral single dose; Active metabolite; normal,healthy;",149.01
DDPD06402,Telavancin,CCCCCCCCCCNCCN[C@@]1(C)C[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2OC2=C3OC4=CC=C(C=C4Cl)[C@@H](O)[C@@H](NC(=O)[C@@H](CC(C)C)NC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]4C(C=C2OC2=C(Cl)C=C(C=C2)[C@@H](O)[C@@H]2NC(=O)[C@H](NC4=O)C4=CC(=C(O)C=C4)C4=C(O)C(CNCP(O)(O)=O)=C(O)C=C4[C@H](NC2=O)C(O)=O)=C3)O[C@@H](C)[C@H]1O,1755.65,93600.0,ng/ml,93.6±14.2,"intravenous injection, IV;",53313.59
DDPD06480,Prucalopride,COCCCN1CCC(CC1)NC(=O)C1=C2OCCC2=C(N)C(Cl)=C1,367.87,3.79,ng/ml,3.79,,10.30
DDPD06589,Pazopanib,CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1,437.518,58100.0,ng/ml,58.1,"PO, oral;",132794.54
DDPD06616,Bosutinib,COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl,530.446,200.0,ng/ml,200,"PO, oral; Chronic myelogenous leukemia; food;",377.04
DDPD06637,Dalfampridine,NC1=CC=NC=C1,94.1145,19.45,ng/ml,17.3-21.6,"PO, oral; extended release formulation;",206.66
DDPD06699,Degarelix,CC(C)C[C@H](NC(=O)[C@@H](CC1=CC=C(NC(N)=O)C=C1)NC(=O)[C@H](CC1=CC=C(NC(=O)[C@@H]2CC(=O)NC(=O)N2)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CC=CN=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC=C2C=CC=CC2=C1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,1632.29,330.0,ng/ml,330,"subcutaneous injection, SC;",202.17
DDPD06716,Fospropofol,CC(C)C1=CC=CC(C(C)C)=C1OCOP(O)(O)=O,288.2766,78700.0,ng/ml,78.7,"intravenous injection, IV; normal,healthy;",273001.69
DDPD06755,Beta carotene,C\C(\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)CCCC1(C)C,536.888,0.58,ng/ml,0.58,Oral single dose;,1.08
DDPD06756,Glycine betaine,C[N+](C)(C)CC([O-])=O,117.1463,105431.67,ng/ml,0.9±0.2,Oral single dose;,900000.00
DDPD06772,Cabazitaxel,[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C4=CC=CC=C4)C(C)=C([C@@H](OC)C(=O)[C@]1(C)[C@H](C[C@H]1OC[C@@]21OC(C)=O)OC)C3(C)C,835.9324,226.0,ng/ml,226,"intravenous injection, IV; metastatic prostate cancer;",270.36
DDPD06774,Capsaicin,COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1,305.4119,2.47,ng/ml,2.47±0.13,"PO, oral;",8.09
DDPD06774,Capsaicin,COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1,305.4119,1.86,ng/ml,1.86,skin/dermal;,6.09
DDPD06775,Carglumic acid,NC(=O)N[C@@H](CCC(O)=O)C(O)=O,190.154,2600.0,ng/ml,2.6(1.9-4.8),,13673.13
DDPD06788,Histrelin,CC(O)=O.CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC1=CN(CC2=CC=CC=C2)C=N1)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1,1443.632,1.1,ng/ml,1.10±0.375,subdermal implant;,0.76
DDPD06800,Methylnaltrexone,C[N@+]1(CC2CC2)CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@]2(O)CCC4=O)=C35,356.441,117.0,ng/ml,117,,328.25
DDPD06809,Plerixafor,C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1,502.782,0.24,ng/mg,0.24,"subcutaneous injection, SC;",0.48
DDPD06819,Phenylbutyric acid,OC(=O)CCCC1=CC=CC=C1,164.2011,218000.0,ng/ml,218,"Tablet, PO, oral; fasting;",1327640.31
DDPD06819,Phenylbutyric acid,OC(=O)CCCC1=CC=CC=C1,164.2011,195000.0,ng/ml,195,"PO, oral; fasting;",1187568.17
DDPD06826,Unoprostone,CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O,382.541,1.5,ng/ml,<1.5,ophthalmic administration;,3.92
DDPD07565,Chloramphenicol succinate,O[C@@H]([C@@H](COC(=O)CCC(O)=O)NC(=O)C(Cl)Cl)C1=CC=C(C=C1)[N+]([O-])=O,423.202,11210.0,ng/ml,11.21±3.42,,26488.53
DDPD08814,Triflusal,CC(=O)OC1=C(C=CC(=C1)C(F)(F)F)C(O)=O,248.157,11600.0,ng/ml,11.6,,46744.60
DDPD08814,Triflusal,CC(=O)OC1=C(C=CC(=C1)C(F)(F)F)C(O)=O,248.157,92700.0,ng/ml,92.7,,373553.84
DDPD08816,Ticagrelor,CCCSC1=NC2=C(N=NN2[C@@H]2C[C@H](OCCO)[C@@H](O)[C@H]2O)C(N[C@@H]2C[C@H]2C2=CC(F)=C(F)C=C2)=N1,522.568,923.0,ng/ml,923,Oral single dose;,1766.28
DDPD08816,Ticagrelor,CCCSC1=NC2=C(N=NN2[C@@H]2C[C@H](OCCO)[C@@H](O)[C@H]2O)C(N[C@@H]2C[C@H]2C2=CC(F)=C(F)C=C2)=N1,522.568,264.0,ng/ml,264,Oral single dose; Active metabolite;,505.20
DDPD08819,Tafluprost,CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COC1=CC=CC=C1,452.5313,0.026,ng/ml,26,ophthalmic administration; Active metabolite;,0.06
DDPD08820,Ivacaftor,CC(C)(C)C1=CC(=C(O)C=C1NC(=O)C1=CNC2=CC=CC=C2C1=O)C(C)(C)C,392.4907,768.0,ng/ml,768,"PO, oral; high-fat meal;",1956.73
DDPD08867,Ulipristal,CN(C)C1=CC=C(C=C1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12,433.592,176.0,ng/ml,176±89,"Oral single dose; normal,healthy;",405.91
DDPD08874,Fidaxomicin,[H][C@@]1(O[C@@H]2[C@@H](CC)\C=C(C)\[C@@H](O)C\C=C\C=C(CO[C@@H]3O[C@H](C)[C@@H](OC(=O)C4=C(CC)C(Cl)=C(O)C(Cl)=C4O)[C@H](O)[C@@H]3OC)\C(=O)O[C@@H](C\C=C(/C)\C=C2/C)[C@@H](C)O)OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@@H]1O,1058.05,5.2,ng/ml,5.20±2.81,"PO, oral; normal,healthy; adults;",4.91
DDPD08874,Fidaxomicin,[H][C@@]1(O[C@@H]2[C@@H](CC)\C=C(C)\[C@@H](O)C\C=C\C=C(CO[C@@H]3O[C@H](C)[C@@H](OC(=O)C4=C(CC)C(Cl)=C(O)C(Cl)=C4O)[C@H](O)[C@@H]3OC)\C(=O)O[C@@H](C\C=C(/C)\C=C2/C)[C@@H](C)O)OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@@H]1O,1058.05,12.0,ng/ml,12.0±6.06,"PO, oral; normal,healthy; adults; Active metabolite;",11.34
DDPD08877,Ruxolitinib,N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1,306.365,198.830885,ng/ml,649,"PO, oral; normal,healthy;",649.00
DDPD08881,Vemurafenib,CCCS(=O)(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1,489.922,62000.0,ng/ml,62,"PO, oral; patients;",126550.76
DDPD08889,Carfilzomib,CC(C)C[C@H](NC(=O)[C@H](CCC1=CC=CC=C1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,719.9099,4232.0,ng/ml,4232,,5878.51
DDPD08896,Regorafenib,CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1,482.815,2500.0,ng/ml,2.5,,5177.97
DDPD08901,Ponatinib,CN1CCN(CC2=CC=C(NC(=O)C3=CC(C#CC4=CN=C5C=CC=NN45)=C(C)C=C3)C=C2C(F)(F)F)CC1,532.5595,73.0,ng/ml,73,,137.07
DDPD08903,Bedaquiline,COC1=NC2=C(C=C(Br)C=C2)C=C1[C@@H](C1=CC=CC=C1)[C@@](O)(CCN(C)C)C1=CC=CC2=C1C=CC=C2,555.505,5500.0,ng/ml,5.5,"PO, oral;",9900.90
DDPD08905,Formestane,[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=C(O)C(=O)CC[C@]12C,302.4079,14.5155792,ng/ml,48±20.9,"IM,intramuscular injection;",48.00
DDPD08908,Dimethyl fumarate,[H]\C(=C(\[H])C(=O)OC)C(=O)OC,144.1253,1870.0,ng/ml,1.87,Active metabolite;,12974.82
DDPD08909,Glycerol phenylbutyrate,O=C(CCCC1=CC=CC=C1)OCC(COC(=O)CCCC1=CC=CC=C1)OC(=O)CCCC1=CC=CC=C1,530.6512,37000.0,ng/ml,37.0,Oral single dose; fasting; Active metabolite;,69725.65
DDPD08909,Glycerol phenylbutyrate,O=C(CCCC1=CC=CC=C1)OCC(COC(=O)CCCC1=CC=CC=C1)OC(=O)CCCC1=CC=CC=C1,530.6512,14900.0,ng/ml,14.9,Oral single dose; fasting; Active metabolite;,28078.71
DDPD08909,Glycerol phenylbutyrate,O=C(CCCC1=CC=CC=C1)OCC(COC(=O)CCCC1=CC=CC=C1)OC(=O)CCCC1=CC=CC=C1,530.6512,30200.0,ng/ml,30.2,Oral single dose; fasting; Active metabolite;,56911.21
DDPD08910,Pomalidomide,NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O,273.2441,75.0,ng/ml,75,"PO, oral; multiple myeloma;",274.48
DDPD08911,Trametinib,CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1,615.3948,22.2,ng/ml,22.2,"PO, oral;",36.07
DDPD08917,Ferric carboxymaltose,C(C1C(C(C(C(O1)OC2C(OC(C(C2O)O)OC3C(OC(C(C3O)O)OC(C(CO)O)C(C(C(=O)[O-])O)O)CO)CO)O)O)O)O.O.[OH-].[O-2].[Fe+3],N.A.,185000.0,ng/ml,37-333,"PO, oral; iron deficient;",
DDPD08918,Levomilnacipran,CCN(CC)C(=O)[C@]1(C[C@H]1CN)C1=CC=CC=C1,246.348,341.0,ng/ml,341,"Capsule, PO, Oral; extended release formulation;",1384.22
DDPD08930,Dolutegravir,[H][C@]12CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C(O)=C3C(=O)N1[C@H](C)CCO2,419.3788,3670.0,ng/ml,3.67,"PO, oral; AIDS,HIV;",8751.04
DDPD08930,Dolutegravir,[H][C@]12CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C(O)=C3C(=O)N1[C@H](C)CCO2,419.3788,3490.0,ng/ml,3.49,"PO, oral; Caucasian; AIDS,HIV;",8321.83
DDPD08933,Luliconazole,ClC1=CC(Cl)=C(C=C1)[C@@H]1CS\C(S1)=C(\C#N)N1C=CN=C1,354.27,0.4,ng/ml,0.40±0.76,"PO, oral; tinea pedis;",1.13
DDPD08934,Sofosbuvir,CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1,529.458,567.0,ng/ml,567,"PO, oral;",1070.91
DDPD09027,Ledipasvir,COC(=O)N[C@@H](C(C)C)C(=O)N1CC2(CC2)C[C@H]1C1=NC(=CN1)C1=CC=C2C3=CC=C(C=C3C(F)(F)C2=C1)C1=CC=C2NC(=NC2=C1)[C@@H]1[C@H]2CC[C@H](C2)N1C(=O)[C@@H](NC(=O)OC)C(C)C,888.9999,323.0,ng/ml,323,"PO, oral;",363.33
DDPD09038,Empagliflozin,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC=C(Cl)C(CC2=CC=C(O[C@H]3CCOC3)C=C2)=C1,450.91,116.78569,ng/ml,259,"PO, oral;",259.00
DDPD09038,Empagliflozin,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC=C(Cl)C(CC2=CC=C(O[C@H]3CCOC3)C=C2)=C1,450.91,309.77517,ng/ml,687,"PO, oral;",687.00
DDPD09042,Tedizolid phosphate,CN1N=NC(=N1)C1=CC=C(C=N1)C1=CC=C(C=C1F)N1C[C@H](COP(O)(O)=O)OC1=O,450.323,2000.0,ng/ml,2.0±0.7,Oral single dose;,4441.26
DDPD09042,Tedizolid phosphate,CN1N=NC(=N1)C1=CC=C(C=N1)C1=CC=C(C=C1F)N1C[C@H](COP(O)(O)=O)OC1=O,450.323,2300.0,ng/ml,2.3±0.6,,5107.45
DDPD09050,Ceftolozane,CN1C(N)=C(NC(=O)NCCN)C=[N+]1CC1=C(N2[C@H](SC1)[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=NSC(N)=N1)C2=O)C([O-])=O,666.69,69100.0,ng/ml,69.1,"intravenous injection, IV;",103646.37
DDPD09053,Ibrutinib,NC1=NC=NC2=C1C(=NN2[C@@H]1CCCN(C1)C(=O)C=C)C1=CC=C(OC2=CC=CC=C2)C=C1,440.507,35.0,ng/ml,35,"PO, oral;",79.45
DDPD09061,Cannabidiol,CCCCCC1=CC(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1,314.469,2.5,ng/ml,2.50,sublingual; Derivative;,7.95
DDPD09061,Cannabidiol,CCCCCC1=CC(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1,314.469,3.02,ng/ml,3.02,buccal; Derivative;,9.60
DDPD09074,Olaparib,FC1=CC=C(CC2=NNC(=O)C3=CC=CC=C23)C=C1C(=O)N1CCN(CC1)C(=O)C1CC1,434.4628,6900.0,ng/ml,4.7-9.1,"PO, oral;",15881.68
DDPD09095,Difluocortolone,[H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,394.459,0.75,ng/ml,0.75,Rectal Administration;,1.90
DDPD09106,Hydroxyethyl Starch,C(COCC1C(C(C(C(O1)OCCO)OCCO)OCCO)OCCO)O.C(C1C(C(C(C(O1)O)O)O)O)O,N.A.,4340000.0,ng/ml,4.34,,
DDPD09116,Calcium carbimide,[Ca++].[N-]=C=[N-],80.103,1650.0,ng/ml,1.65,,20598.48
DDPD09121,Aurothioglucose,OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O,392.18,3425000000.0,ng/ml,342.5,,8733234739.15
DDPD09123,Dienogest,[H][C@@]12CC[C@@](O)(CC#N)[C@@]1(C)CCC1=C3CCC(=O)C=C3CC[C@@]21[H],311.425,47.0,ng/ml,47,Oral single dose;,150.92
DDPD09124,Medrogestone,[H][C@@]12CC[C@](C)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C,340.507,12.5,ng/ml,10-15,"PO, oral;",36.71
DDPD09146,Iron sucrose,O.O.O.[OH-].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Na+].[Na+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O,866.546,30000.0,ng/ml,30,"intravenous injection, IV;",34620.20
DDPD09167,Dosulepin,CN(C)CC\C=C1/C2=CC=CC=C2CSC2=CC=CC=C12,295.44,37.6,ng/ml,37.6,"PO, oral;",127.27
DDPD09185,Viloxazine,CCOC1=CC=CC=C1OCC1CNCCO1,237.299,1070.0,ng/ml,540-1600,"PO, oral;",4509.08
DDPD09205,Moxisylyte,CC(C)C1=C(OCCN(C)C)C=C(C)C(OC(C)=O)=C1,279.38,352.8,ng/ml,352.8,"intravenous injection, IV;",1262.80
DDPD09209,Pholcodine,[H][C@@]12OC3=C(OCCN4CCOCC4)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O,398.4953,26.3,ng/ml,26.3,"PO, oral;",66.00
DDPD09210,Piracetam,NC(=O)CN1CCCC1=O,142.1558,84000.0,ng/ml,84,Oral single dose;,590900.97
DDPD09216,Tolfenamic acid,CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O,261.704,11100.0,ng/ml,11.1,"PO, oral;",42414.33
DDPD09220,Nicorandil,[O-][N+](=O)OCCNC(=O)C1=CC=CN=C1,211.177,300.0,ng/ml,300,"PO, oral;",1420.61
DDPD09225,Zotepine,CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12,331.86,13.25,ng/ml,6.9-19.6,increasing doses;,39.93
DDPD09236,Lacidipine,CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C)C(=O)OCC,455.551,3.65,ng/ml,1.6-5.7,"Oral single dose; normal,healthy; adults;",8.01
DDPD09237,Levamlodipine,CCOC(=O)C1=C(COCCN)NC(C)=C([C@@H]1C1=CC=CC=C1Cl)C(=O)OC,408.88,6.13,ng/ml,6.13±1.29,"PO, oral; Derivative;",14.99
DDPD09237,Levamlodipine,CCOC(=O)C1=C(COCCN)NC(C)=C([C@@H]1C1=CC=CC=C1Cl)C(=O)OC,408.88,5.07,ng/ml,5.07±1.09,"PO, oral; Derivative;",12.40
DDPD09268,Picosulfuric acid,OS(=O)(=O)OC1=CC=C(C=C1)C(C1=CC=C(OS(O)(=O)=O)C=C1)C1=CC=CC=N1,437.44,0.05,ng/ml,0.05,Active metabolite;,0.11
DDPD09270,Ubidecarenone,COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O,863.3435,320.0,ng/ml,0.32,"PO, oral;",370.65
DDPD09274,Artesunate,[H][C@@]12CC[C@@H](C)[C@]3([H])CC[C@@]4(C)OO[C@@]13[C@]([H])(O[C@@H](OC(=O)CCC(O)=O)[C@@H]2C)O4,384.425,3300.0,ng/ml,3.3,,8584.25
DDPD09274,Artesunate,[H][C@@]12CC[C@@H](C)[C@]3([H])CC[C@@]4(C)OO[C@@]13[C@]([H])(O[C@@H](OC(=O)CCC(O)=O)[C@@H]2C)O4,384.425,3100.0,ng/ml,3.1,Active metabolite;,8063.99
DDPD09275,Bismuth subcitrate potassium,[K+].[K+].[K+].[K+].[K+].[Bi+3].[O-]C(=O)CC([O-])(CC([O-])=O)C([O-])=O.[O-]C(=O)CC([O-])(CC([O-])=O)C([O-])=O,780.654,50000.0,ng/ml,>50,,64048.86
DDPD09297,Paritaprevir,[H][C@@]12C[C@]1(NC(=O)[C@]1([H])C[C@H](CN1C(=O)[C@H](CCCCC\C=C/2)NC(=O)C1=CN=C(C)C=N1)OC1=NC2=C(C=CC=C2)C2=C1C=CC=C2)C(=O)NS(=O)(=O)C1CC1,765.89,194.0,ng/ml,194,,253.30
DDPD09299,Tenofovir alafenamide,CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)CN1C=NC2=C(N)N=CN=C12)OC1=CC=CC=C1,476.474,16.0,ng/ml,16,Oral single dose;,33.58
DDPD09301,Chondroitin sulfate,CC(=O)NC1C(C(C(OC1O)OS(=O)(=O)O)O)OC2C(C(C(C(O2)C(=O)O)O)O)O,N.A.,4600.0,ng/ml,4.6,"PO, oral;",
DDPD09301,Chondroitin sulfate,CC(=O)NC1C(C(C(OC1O)OS(=O)(=O)O)O)OC2C(C(C(C(O2)C(=O)O)O)O)O,N.A.,3800.0,ng/ml,3.8,"IM,intramuscular injection;",
DDPD09313,Ioxaglic acid,CNC(=O)C1=C(I)C(C(=O)NCC(=O)NC2=C(I)C(C(O)=O)=C(I)C(C(=O)NCCO)=C2I)=C(I)C(N(C)C(C)=O)=C1I,1268.886,2100000.0,ng/ml,2.1(1.8-2.8),"intravenous injection, IV; normal,healthy;",1654995.01
DDPD09324,Sulbactam,[H][C@@]12CC(=O)N1[C@@]([H])(C(O)=O)C(C)(C)S2(=O)=O,233.242,68000.0,ng/ml,48-88,,291542.69
DDPD09324,Sulbactam,[H][C@@]12CC(=O)N1[C@@]([H])(C(O)=O)C(C)(C)S2(=O)=O,233.242,15000.0,ng/ml,6-24,,64310.89
DDPD09325,Sodium fluoride,[F-].[Na+],41.9882,848.0,ng/ml,848±116,Liquid;,20196.15
DDPD09343,Tipiracil,ClC1=C(CN2CCCC2=N)NC(=O)NC1=O,242.662,69.0,ng/ml,69,Oral single dose;,284.35
DDPD09419,Xylose,OC[C@@H](O)[C@H](O)[C@@H](O)C=O,150.1299,530.0,ng/ml,0.53,,3530.28
DDPD09496,Octinoxate,[H]\C(=C(\[H])C1=CC=C(OC)C=C1)C(=O)OCC(CC)CCCC,290.3972,7.0,ng/ml,7,"skin/dermal; Male, men;",24.10
DDPD09496,Octinoxate,[H]\C(=C(\[H])C1=CC=C(OC)C=C1)C(=O)OCC(CC)CCCC,290.3972,16.0,ng/ml,16,"skin/dermal;  Female, women;",55.10
DDPD09517,Sodium ferric gluconate complex,[O--].[O--].[O--].[Na+].[Fe+3].[Fe+3].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O,2089.309,9.92,ng/ml,9.92(4.22-23.62),"skin/dermal; normal,healthy;",4.75
DDPD11068,Selenic acid,O[Se](O)(=O)=O,144.97,1665.0,ng/ml,0.79-2.54,"PO, oral; sheep;",11485.13
DDPD11168,Calcium threonate,[Ca++].OC[C@H](O)[C@@H](O)C([O-])=O.OC[C@H](O)[C@@H](O)C([O-])=O,310.268,32300.0,ng/ml,32.3,"Oral single dose; normal,healthy; Asian;",104103.55
DDPD11219,Enzacamene,CC1=CC=C(\C=C2/C3CCC(C)(C2=O)C3(C)C)C=C1,254.373,16.0,ng/ml,16,"skin/dermal; normal,healthy;  Female, women;",62.90
DDPD11256,Levomefolic acid,CN1[C@@H](CNC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNC2=C1C(=O)N=C(N)N2,459.4558,18.10255852,ng/ml,39.4,"Oral single dose;  Female, women;",39.40
DDPD11273,Dihydroergocornine,[H][C@@]12CCCN1C(=O)[C@H](C(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)(O[C@@]21O)C(C)C,563.699,0.57,ngEq/ml,0.57,"PO, oral;",1.01
DDPD11274,Dihydro-alpha-ergocryptine,[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)(O[C@@]21O)C(C)C,577.726,2.157,ng/ml,2157,Oral multiple dose;,3.73
DDPD11431,Moxidectin,[H][C@@]12OC\C3=C/C=C/[C@H](C)C\C(C)=C\C[C@]4([H])C[C@@]([H])(C[C@]5(C\C(=N/OC)[C@H](C)[C@H](O5)C(\C)=C\C(C)C)O4)OC(=O)[C@]([H])(C=C(C)[C@H]1O)[C@@]23O,639.83,70.4,ng/mg,70.4,,110.03
DDPD11581,Venetoclax,CC1(C)CCC(CN2CCN(CC2)C2=CC=C(C(=O)NS(=O)(=O)C3=CC=C(NCC4CCOCC4)C(=C3)[N+]([O-])=O)C(OC3=CN=C4NC=CC4=C3)=C2)=C(C1)C1=CC=C(Cl)C=C1,868.45,2100.0,ng/ml,2.1±1.1,"PO, oral; low fat meal;",2418.10
DDPD11586,Asunaprevir,COC1=CN=C(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)C2=C1C=CC(Cl)=C2,748.286,572.0,ng/ml,572,,764.41
DDPD11587,Etafedrine,CCN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1,193.29,100.0,ng/ml,0.10,"PO, oral;",517.36
DDPD11596,Levoleucovorin,NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1,473.4393,1722.0,ng/ml,1722,"intravenous injection, IV; Derivative;",3637.21
DDPD11596,Levoleucovorin,NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1,473.4393,275.0,ng/ml,275,"intravenous injection, IV; Derivative;",580.86
DDPD11611,Lifitegrast,CS(=O)(=O)C1=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(CN(CC3)C(=O)C3=CC=C4C=COC4=C3)C=C2Cl)C(O)=O)=CC=C1,615.48,1.7,ng/ml,1.70,,2.76
DDPD11611,Lifitegrast,CS(=O)(=O)C1=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(CN(CC3)C(=O)C3=CC=C4C=COC4=C3)C=C2Cl)C(O)=O)=CC=C1,615.48,2.145,ng/ml,0.55-3.74,different study;,3.49
DDPD11633,Isavuconazole,C[C@@H](C1=NC(=CS1)C1=CC=C(C=C1)C#N)[C@](O)(CN1C=NC=N1)C1=C(F)C=CC(F)=C1,437.47,7499.0,ng/ml,7499,"PO, oral;",17141.75
DDPD11633,Isavuconazole,C[C@@H](C1=NC(=CS1)C1=CC=C(C=C1)C#N)[C@](O)(CN1C=NC=N1)C1=C(F)C=CC(F)=C1,437.47,20028.0,ng/ml,20028,"PO, oral;",45781.43
DDPD11637,Delamanid,C[C@]1(COC2=CC=C(C=C2)N2CCC(CC2)OC2=CC=C(OC(F)(F)F)C=C2)CN2C=C(N=C2O1)[N+]([O-])=O,534.492,135.0,ng/ml,135,Oral single dose;,252.58
DDPD11640,Amifampridine,NC1=CC=NC=C1N,109.132,76.5,ng/ml,16-137,Oral single dose; fasting;,700.99
DDPD11642,Pitolisant,ClC1=CC=C(CCCOCCCN2CCCCC2)C=C1,295.85,30.0,ng/ml,~30,"PO, oral;",101.40
DDPD11642,Pitolisant,ClC1=CC=C(CCCOCCCN2CCCCC2)C=C1,295.85,73.0,ng/ml,73,Oral multiple dose;,246.75
DDPD11644,Tafamidis,OC(=O)C1=CC=C2N=C(OC2=C1)C1=CC(Cl)=CC(Cl)=C1,308.116,1430.93,ng/ml,1430.93,"PO, oral; fasting;",4644.13
DDPD11652,Tucatinib,CC1=CC(NC2=NC=NC3=CC=C(NC4=NC(C)(C)CO4)C=C23)=CC=C1OC1=CC2=NC=NN2C=C1,480.532,1120.0,ng/ml,1120,different study;,2330.75
DDPD11653,Bremelanotide,CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](CC2=CNC3=CC=CC=C23)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CN=CN2)NC1=O)C(O)=O,1025.182,72.8,ng/ml,72.8,,71.01
DDPD11660,Latanoprostene bunod,O[C@H](CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OCCCCO[N+]([O-])=O)CCC1=CC=CC=C1,507.624,0.0591,ng/ml,59.1,"normal,healthy; Derivative;",0.12
DDPD11672,Curcumin,COC1=CC(\C=C\C(=O)CC(=O)\C=C\C2=CC(OC)=C(O)C=C2)=CC=C1O,368.3799,5000.0,ng/ml,<5,Oral single dose;,13572.94
DDPD11712,Tezacaftor,CC(C)(CO)C1=CC2=CC(NC(=O)C3(CC3)C3=CC=C4OC(F)(F)OC4=C3)=C(F)C=C2N1C[C@@H](O)CO,520.505,5950.0,ng/ml,5.95,combination drug use;,11431.21
DDPD11732,Lasmiditan,CN1CCC(CC1)C(=O)C1=CC=CC(NC(=O)C2=C(F)C=C(F)C=C2F)=N1,377.367,322.8,ng/ml,322.8±122.0,"PO, oral;",855.40
DDPD11732,Lasmiditan,CN1CCC(CC1)C(=O)C1=CC=CC(NC(=O)C2=C(F)C=C(F)C=C2F)=N1,377.367,393.82,ng/ml,393.82,"PO, oral; high-fat meal;",1043.60
DDPD11753,Rifamycin,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C=C(O)C4=C3C2=O,697.778,2.0,ng/ml,<2,"PO, oral; patients;",2.87
DDPD11753,Rifamycin,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C=C(O)C4=C3C2=O,697.778,36000.0,ng/ml,36,"PO, oral;",51592.34
DDPD11757,Istradefylline,[H]\C(=C(\[H])C1=CC(OC)=C(OC)C=C1)C1=NC2=C(N1C)C(=O)N(CC)C(=O)N2CC,384.436,181.1,ng/ml,181.1,,471.08
DDPD11757,Istradefylline,[H]\C(=C(\[H])C1=CC(OC)=C(OC)C=C1)C1=NC2=C(N1C)C(=O)N(CC)C(=O)N2CC,384.436,4.34,ng/ml,4.34,Active metabolite;,11.29
DDPD11757,Istradefylline,[H]\C(=C(\[H])C1=CC(OC)=C(OC)C=C1)C1=NC2=C(N1C)C(=O)N(CC)C(=O)N2CC,384.436,12.6,ng/ml,12.6,Active metabolite;,32.78
DDPD11793,Niraparib,NC(=O)C1=CC=CC2=CN(N=C12)C1=CC=C(C=C1)[C@@H]1CCCNC1,320.396,804.0,ng/ml,804±403,Oral single dose;,2509.39
DDPD11827,Ertugliflozin,CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@]23OC[C@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)C=C1,436.89,268.0,ng/ml,268,"PO, oral;",613.43
DDPD11855,Revefenacin,CN(CCN1CCC(CC1)OC(=O)NC1=CC=CC=C1C1=CC=CC=C1)C(=O)C1=CC=C(CN2CCC(CC2)C(N)=O)C=C1,597.76,0.085,ng/ml,0.02-0.15,,0.14
DDPD11901,Apalutamide,CNC(=O)C1=CC=C(C=C1F)N1C(=S)N(C(=O)C11CCC1)C1=CC(=C(N=C1)C#N)C(F)(F)F,477.44,6000.0,ng/ml,6.0,"PO, oral;",12567.02
DDPD11901,Apalutamide,CNC(=O)C1=CC=C(C=C1F)N1C(=S)N(C(=O)C11CCC1)C1=CC(=C(N=C1)C#N)C(F)(F)F,477.44,5900.0,ng/ml,5.9,Active metabolite;,12357.57
DDPD11942,Selinexor,FC(F)(F)C1=CC(=CC(=C1)C1=NN(\C=C/C(=O)NNC2=NC=CN=C2)C=N1)C(F)(F)F,443.313,680.0,ng/ml,680,Oral single dose;,1533.90
DDPD11952,Duvelisib,C[C@H](NC1=C2N=CNC2=NC=N1)C1=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1,416.87,1882.5,ng/ml,471-3294,,4515.80
DDPD11963,Dacomitinib,COC1=C(NC(=O)\C=C\CN2CCCCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1,469.939,104.0,ng/ml,104,"PO, oral;",221.31
DDPD11978,Glasdegib,CN1CC[C@H](C[C@@H]1C1=NC2=CC=CC=C2N1)NC(=O)NC1=CC=C(C=C1)C#N,374.448,321.0,ng/ml,321,,857.26
DDPD11978,Glasdegib,CN1CC[C@H](C[C@@H]1C1=NC2=CC=CC=C2N1)NC(=O)NC1=CC=C(C=C1)C#N,374.448,542.0,ng/ml,542,Oral multiple dose;,1447.46
DDPD11995,Avatrombopag,OC(=O)C1CCN(CC1)C1=C(Cl)C=C(C=N1)C(=O)NC1=NC(C2=CC(Cl)=CS2)=C(S1)N1CCN(CC1)C1CCCCC1,649.65,166.0,ng/ml,166,"normal,healthy;",255.52
DDPD12001,Abemaciclib,CCN1CCN(CC2=CC=C(NC3=NC=C(F)C(=N3)C3=CC(F)=C4N=C(C)N(C(C)C)C4=C3)N=C2)CC1,506.606,158.0,ng/ml,158,Oral single dose;,311.88
DDPD12015,Alpelisib,CC1=C(SC(NC(=O)N2CCC[C@H]2C(N)=O)=N1)C1=CC(=NC=C1)C(C)(C)C(F)(F)F,441.47,1320.0,ng/ml,1320±912,,2990.01
DDPD12015,Alpelisib,CC1=C(SC(NC(=O)N2CCC[C@H]2C(N)=O)=N1)C1=CC(=NC=C1)C(C)(C)C(F)(F)F,441.47,2429.0,ng/ml,2429,"PO, oral; high-fat meal;",5502.07
DDPD12015,Alpelisib,CC1=C(SC(NC(=O)N2CCC[C@H]2C(N)=O)=N1)C1=CC(=NC=C1)C(C)(C)C(F)(F)F,441.47,2831.0,ng/ml,2831,"PO, oral; low fat meal;",6412.67
DDPD12026,Voxilaprevir,CC[C@@H]1[C@@H]2CN([C@@H]1C(=O)N[C@@]1(C[C@H]1C(F)F)C(=O)NS(=O)(=O)C1(C)CC1)C(=O)[C@@H](NC(=O)O[C@@H]1C[C@H]1CCCCC(F)(F)C1=C(O2)N=C2C=C(OC)C=CC2=N1)C(C)(C)C,868.94,192.0,ng/ml,192,combination drug use;,220.96
DDPD12107,Vaborbactam,OB1O[C@H](CC(O)=O)CC[C@@H]1NC(=O)CC1=CC=CS1,297.13,55600.0,ng/ml,55.6,"normal,healthy; adults;",187123.48
DDPD12107,Vaborbactam,OB1O[C@H](CC(O)=O)CC[C@@H]1NC(=O)CC1=CC=CS1,297.13,71300.0,ng/ml,71.3,patients; adults;,239962.31
DDPD12141,Gilteritinib,CCC1=C(NC2CCOCC2)N=C(NC2=CC=C(N3CCC(CC3)N3CCN(C)CC3)C(OC)=C2)C(=N1)C(N)=O,552.724,374.0,ng/ml,374,"PO, oral;",676.65
DDPD12147,Erdafitinib,COC1=CC(=CC(OC)=C1)N(CCNC(C)C)C1=CC=C2N=CC(=NC2=C1)C1=CN(C)N=C1,446.555,1399.0,ng/ml,1399,,3132.87
DDPD12243,Edaravone,CC1=NN(C(=O)C1)C1=CC=CC=C1,174.203,888.0,ng/ml,888,"intravenous infusion, IV in drop; normal,healthy; Male, men; adults;",5097.50
DDPD12245,Triclabendazole,CSC1=NC2=C(N1)C=C(Cl)C(OC1=CC=CC(Cl)=C1Cl)=C2,359.65,1.16,ng/ml,1.16,Oral single dose; fascioliasis; food;,3.23
DDPD12245,Triclabendazole,CSC1=NC2=C(N1)C=C(Cl)C(OC1=CC=CC(Cl)=C1Cl)=C2,359.65,38.6,ng/ml,38.6,Oral single dose; fascioliasis; food; Components;,107.33
DDPD12245,Triclabendazole,CSC1=NC2=C(N1)C=C(Cl)C(OC1=CC=CC(Cl)=C1Cl)=C2,359.65,2.29,ng/ml,2.29,Oral single dose; fascioliasis; food; Active metabolite;,6.37
DDPD12267,Brigatinib,COC1=CC(=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1)N1CCC(CC1)N1CCN(C)CC1,584.1,552.0,ng/ml,552,,945.04
DDPD12267,Brigatinib,COC1=CC(=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1)N1CCC(CC1)N1CCN(C)CC1,584.1,1452.0,ng/ml,1452,,2485.88
DDPD12332,Rucaparib,CNCC1=CC=C(C=C1)C1=C2CCNC(=O)C3=C2C(N1)=CC(F)=C3,323.371,1940.0,ng/ml,1940,,5999.30
DDPD12466,Favipiravir,NC(=O)C1=NC(F)=CN=C1O,157.104,51500.0,ng/ml,51.5,,327808.33
DDPD12466,Favipiravir,NC(=O)C1=NC(F)=CN=C1O,157.104,36240.0,ng/ml,36.24,Oral single dose; Asian;,230675.22
DDPD12466,Favipiravir,NC(=O)C1=NC(F)=CN=C1O,157.104,22010.0,ng/ml,22.01,Oral single dose; Caucasian;,140098.28
DDPD12466,Favipiravir,NC(=O)C1=NC(F)=CN=C1O,157.104,36230.0,ng/ml,36.23,Oral multiple dose; Asian;,230611.57
DDPD12466,Favipiravir,NC(=O)C1=NC(F)=CN=C1O,157.104,23940.0,ng/ml,23.94,Oral multiple dose; Caucasian;,152383.13
DDPD12483,Copanlisib,COC1=C(OCCCN2CCOCC2)C=CC2=C1N=C(NC(=O)C1=CN=C(N)N=C1)N1CCN=C21,480.529,463.0,ng/ml,463(105-1670),,963.52
DDPD12500,Fedratinib,CC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C,524.678,1804.0,ng/ml,1804,"PO, oral;",3438.30
DDPD12532,Oxetacaine,CN(C(=O)CN(CCO)CC(=O)N(C)C(C)(C)CC1=CC=CC=C1)C(C)(C)CC1=CC=CC=C1,467.654,20.0,ng/ml,20,"PO, oral;",42.77
DDPD12612,Ozanimod,CC(C)OC1=C(C=C(C=C1)C1=NC(=NO1)C1=C2CC[C@H](NCCO)C2=CC=C1)C#N,404.47,0.244,ng/ml,0.244,"PO, oral;",0.60
DDPD12615,Plazomicin,CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@@H](C[C@H](N)[C@@H](O[C@H]3OC(CNCCO)=CC[C@H]3N)[C@@H]2O)NC(=O)[C@@H](O)CCN)OC[C@]1(C)O,592.691,73700.0,ng/ml,73.7±19.7,"intravenous infusion, IV in drop; normal,healthy; adults;",124348.10
DDPD12615,Plazomicin,CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@@H](C[C@H](N)[C@@H](O[C@H]3OC(CNCCO)=CC[C@H]3N)[C@@H]2O)NC(=O)[C@@H](O)CCN)OC[C@]1(C)O,592.691,51000.0,ng/ml,51.0±26.7,"intravenous infusion, IV in drop; complicated urinary tract infections; adults;",86048.21
DDPD12674,Lurbinectedin,[H][C@@]12[C@@H]3SC[C@]4(NCCC5=C4NC4=CC=C(OC)C=C54)C(=O)OC[C@H](N1[C@@H](O)[C@@H]1CC4=CC(C)=C(OC)C(O)=C4[C@@]2([H])N1C)C1=C2OCOC2=C(C)C(OC(C)=O)=C31,784.88,107.0,ng/ml,107,"intravenous injection, IV;",136.33
DDPD12808,Trifarotene,CC(C)(C)C1=CC(=CC=C1N1CCCC1)C1=CC(=CC=C1OCCO)C1=CC=C(C=C1)C(O)=O,459.586,0.005,ng/ml,0-10,,0.01
DDPD12825,Lefamulin,[H][C@@]12C(=O)CC[C@]11CCC(C)[C@@]2(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]1C)OC(=O)CS[C@@H]1CC[C@@H](N)C[C@H]1O,507.73,37100.0,ng/ml,37.1,"PO, oral;",73070.33
DDPD12834,Secnidazole,CC(O)CN1C(C)=NC=C1N(=O)=O,185.183,45400.0,ng/ml,45.4,"PO, oral; normal,healthy;  Female, women;",245162.89
DDPD12839,Pegvaliase,COCCOCCCCCC(=O)NCCCC[C@H](N)C(O)=O,318.414,14000.0,ng/ml,14.0±16.3,,43967.92
DDPD12839,Pegvaliase,COCCOCCCCCC(=O)NCCCC[C@H](N)C(O)=O,318.414,34380.0,ng/ml,0.26-68.5,,107972.64
DDPD12839,Pegvaliase,COCCOCCCCCC(=O)NCCCC[C@H](N)C(O)=O,318.414,16700.0,ng/ml,16.7±19.5,,52447.44
DDPD12839,Pegvaliase,COCCOCCCCCC(=O)NCCCC[C@H](N)C(O)=O,318.414,32020.0,ng/ml,0.24-63.8,,100560.90
DDPD12887,Tazemetostat,CCN(C1CCOCC1)C1=C(C)C(=CC(=C1)C1=CC=C(CN2CCOCC2)C=C1)C(=O)NCC1=C(C)C=C(C)NC1=O,572.75,829.0,ng/ml,829,,1447.40
DDPD12942,Lactitol,OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO,344.3124,776.0,ng/ml,776±253,"PO, oral; normal,healthy; food;",2253.77
DDPD12978,Pexidartinib,FC(F)(F)C1=CC=C(CNC2=NC=C(CC3=CNC4=NC=C(Cl)C=C34)C=C2)C=N1,417.82,8625.0,ng/ml,8625,"PO, oral;",20642.86
DDPD12978,Pexidartinib,FC(F)(F)C1=CC=C(CNC2=NC=C(CC3=CNC4=NC=C(Cl)C=C34)C=C2)C=N1,417.82,17250.0,ng/ml,17250,"PO, oral; high-fat meal;",41285.72
DDPD13125,Lusutrombopag,CCCCCCO[C@@H](C)C1=C(OC)C(=CC=C1)C1=CSC(NC(=O)C2=CC(Cl)=C(\C=C(/C)C(O)=O)C(Cl)=C2)=N1,591.54,111.0,ng/ml,111,"PO, oral; normal,healthy;",187.65
DDPD13178,Inositol,O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O,180.1559,40500.0,ng,36-45,"PO, oral;",224805.29
DDPD13345,Dihydroergocristine,[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)(O[C@@]21O)C(C)C,611.743,0.28,ng/ml,0.28,"PO, oral;",0.46
DDPD13421,Edoxudine,CCC1=CN([C@H]2C[C@H](O)[C@@H](CO)O2)C(=O)NC1=O,256.258,2.4,ng/mg,2.4,"intravenous injection, IV; mouse;",9.37
DDPD13501,Bendazac,OC(=O)COC1=NN(CC2=CC=CC=C2)C2=CC=CC=C12,282.299,45000.0,ng/ml,35-55,"PO, oral; normal,healthy; Derivative;",159405.45
DDPD13615,Mifamurtide,O.[Na+].CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O)C(N)=O)OC(=O)CCCCCCCCCCCCCCC,1277.515,20.0569855,ng/ml,15.7±3.72,"intravenous injection, IV; normal,healthy; adults;",15.70
DDPD13783,Acemetacin,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(=O)OCC(O)=O,415.83,276.8,ng/ml,276.8,"PO, oral; Elderly;",665.66
DDPD13783,Acemetacin,COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(=O)OCC(O)=O,415.83,187.0,ng/ml,187,"PO, oral; young;",449.70
DDPD13853,Anethole trithione,COC1=CC=C(C=C1)C1=CC(=S)SS1,240.35,0.98,ng/ml,0.98±0.49,"normal,healthy; Asian;",4.08
DDPD13874,Enasidenib,CC(C)(O)CNC1=NC(=NC(NC2=CC(=NC=C2)C(F)(F)F)=N1)C1=NC(=CC=C1)C(F)(F)F,473.383,1300.0,ng/ml,1.3,Oral single dose;,2746.19
DDPD13878,Pibrentasvir,CO[C@H](C)[C@H](NC(=O)OC)C(=O)N1CCC[C@H]1C1=NC2=C(N1)C=C(F)C(=C2)[C@H]1CC[C@@H](N1C1=CC(F)=C(N2CCC(CC2)C2=CC=C(F)C=C2)C(F)=C1)C1=CC2=C(NC(=N2)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)OC)[C@@H](C)OC)C=C1F,1113.201,110.0,ng/ml,110,"Hepatitis, Hep;",98.81
DDPD13879,Glecaprevir,[H][C@@]12CN(C(=O)[C@@]([H])(NC(=O)O[C@]3([H])CCC[C@@]3([H])OC\C=C\C(F)(F)C3=NC4=C(C=CC=C4)N=C3O1)C(C)(C)C)[C@@]([H])(C2)C(=O)N[C@@]1(C[C@H]1C(F)F)C(=O)NS(=O)(=O)C1(C)CC1,838.87,597.0,ng/ml,597,"Hepatitis, Hep;",711.67
DDPD13928,Semaglutide,CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O,4113.641,44.8386869,ng/ml,10.9,,10.90
DDPD13943,Testosterone cypionate,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2OC(=O)CCC1CCCC1,412.614,112200.0,ng/ml,1122,"IM,intramuscular injection;",271924.85
DDPD13944,Testosterone enanthate,[H][C@@]12CC[C@H](OC(=O)CCCCCC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C,400.594,120000.0,ng/ml,1200,Multiple dose;,299555.16
DDPD13952,Estradiol acetate,[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(OC(C)=O)C=C3CC[C@@]21[H],314.4186,1.129,ng/ml,1129,,3.59
DDPD13956,Estradiol valerate,[H][C@@]12CC[C@H](OC(=O)CCCC)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3,356.4984,0.0733,ng/ml,73.3,,0.21
DDPD13985,Lutetium Lu 177 dotatate,[177Lu+3].C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN2CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(O)=O,1609.55,10000000.0,ng/ml,10,"intravenous injection, IV;",6212916.65
DDPD13995,Ferric pyrophosphate citrate,[Fe+3].[Fe+3].[Fe+3].[Fe+3].OP(O)(=O)OP(O)(O)=O.OP(O)(=O)OP(O)(O)=O.OP([O-])(=O)OP([O-])([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O,1321.571,1870.0,ng/ml,113-261,,1414.98
DDPD14003,alpha-Tocopherol acetate,CC1=C(C(=C(C2=C1OC(CC2)(C)CCCC(C)CCCC(C)CCCC(C)C)C)OC(=O)C)C,N.A.,1828.0,ng/ml,1828±48.24,"Oral single dose; normal,healthy; Male, men;",
DDPD14003,alpha-Tocopherol acetate,CC1=C(C(=C(C2=C1OC(CC2)(C)CCCC(C)CCCC(C)CCCC(C)C)C)OC(=O)C)C,N.A.,1931.0,ng/ml,1931±92.54,"Oral single dose; normal,healthy; Male, men;",
DDPD14003,alpha-Tocopherol acetate,CC1=C(C(=C(C2=C1OC(CC2)(C)CCCC(C)CCCC(C)CCCC(C)C)C)OC(=O)C)C,N.A.,2188.0,ng/ml,2188±147.61,"Oral single dose; normal,healthy; Male, men;",
DDPD14018,Bromotheophylline,CN1C2=C(NC(Br)=N2)C(=O)N(C)C1=O,259.063,2500.0,ng/ml,2.5,Oral single dose;,9650.16
DDPD14183,Geraniol,CC(C)=CCC\C(C)=C\CO,154.253,270000.0,ng/ml,270.0,"PO, oral; Rattus, Rat;",1750371.14
DDPD14569,Tedizolid,CN1N=NC(=N1)C1=NC=C(C=C1)C1=C(F)C=C(C=C1)N1C[C@H](CO)OC1=O,370.344,2000.0,ng/ml,2.0±0.7,"PO, oral;",5400.38
DDPD14569,Tedizolid,CN1N=NC(=N1)C1=NC=C(C=C1)C1=C(F)C=C(C=C1)N1C[C@H](CO)OC1=O,370.344,3000.0,ng/ml,3.0±0.7,"intravenous injection, IV;",8100.58
DDPD14583,Segesterone acetate,[H][C@@]12CC(=C)[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],370.489,1.147,ng/ml,1147.0,Vaginal Administration; different medication cycle;,3.10
DDPD14583,Segesterone acetate,[H][C@@]12CC(=C)[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],370.489,0.363,ng/ml,363.0,Vaginal Administration; different medication cycle;,0.98
DDPD14583,Segesterone acetate,[H][C@@]12CC(=C)[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H],370.489,0.294,ng/ml,294.0,Vaginal Administration; different medication cycle;,0.79
DDPD14631,Prednisolone phosphate,[H][C@@]12CC[C@](O)(C(=O)COP(O)(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,440.429,461.33,ng/ml,461.33±77.94,Liquid;,1047.46
DDPD14631,Prednisolone phosphate,[H][C@@]12CC[C@](O)(C(=O)COP(O)(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,440.429,420.91,ng/ml,420.91±78.28,"Tablet, PO, oral;",955.68
DDPD14669,Betamethasone phosphate,[H][C@@]12C[C@H](C)[C@](O)(C(=O)COP(O)(O)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,472.446,33.21,ng/ml,33.21±8.71,"IM,intramuscular injection;",70.29
DDPD14669,Betamethasone phosphate,[H][C@@]12C[C@H](C)[C@](O)(C(=O)COP(O)(O)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,472.446,33.21,ng/ml,33.21±8.71,"IM,intramuscular injection; Derivative;",70.29
DDPD14723,Larotrectinib,O[C@H]1CCN(C1)C(=O)NC1=C2N=C(C=CN2N=C1)N1CCC[C@@H]1C1=C(F)C=CC(F)=C1,428.444,788.0,ng/ml,788.0,"Capsule, PO, Oral; adults;",1839.21
DDPD14783,Diroximel fumarate,COC(=O)\C=C\C(=O)OCCN1C(=O)CCC1=O,255.226,2110.0,ng/ml,2.11,"PO, oral;",8267.18
DDPD14879,Cefiderocol,[H][C@]12SCC(C[N+]3(CCNC(=O)C4=C(Cl)C(O)=C(O)C=C4)CCCC3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC(N)=N1)C([O-])=O,752.21,89700.0,ng/ml,89.7,"normal,healthy;",119248.61
DDPD14879,Cefiderocol,[H][C@]12SCC(C[N+]3(CCNC(=O)C4=C(Cl)C(O)=C(O)C=C4)CCCC3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC(N)=N1)C([O-])=O,752.21,138000.0,ng/ml,138.0,"intravenous injection, IV; complicated urinary tract infections;",183459.41
DDPD14975,Voxelotor,CC(C)N1N=CC=C1C1=C(COC2=CC=CC(O)=C2C=O)C=CC=N1,337.379,4950000.0,ug.h/ml,4950.0,Oral multiple dose;,14671926.82
DDPD14975,Voxelotor,CC(C)N1N=CC=C1C1=C(COC2=CC=CC(O)=C2C=O)C=CC=N1,337.379,9610000.0,ug.h/ml,9610.0,Oral multiple dose;,28484286.22
DDPD14975,Voxelotor,CC(C)N1N=CC=C1C1=C(COC2=CC=CC(O)=C2C=O)C=CC=N1,337.379,4000000.0,ug.h/ml,4000.0,Oral multiple dose;,11856102.48
DDPD15035,Zanubrutinib,NC(=O)C1=C2NCC[C@@H](C3CCN(CC3)C(=O)C=C)N2N=C1C1=CC=C(OC2=CC=CC=C2)C=C1,471.561,314.0,ng/ml,314.0,Oral multiple dose;,665.87
DDPD15035,Zanubrutinib,NC(=O)C1=C2NCC[C@@H](C3CCN(CC3)C(=O)C=C)N2N=C1C1=CC=C(OC2=CC=CC=C2)C=C1,471.561,543.0,ng/ml,543.0,Oral multiple dose;,1151.49
DDPD15102,Pemigatinib,CCN1C(=O)N(CC2=CN=C3NC(CN4CCOCC4)=CC3=C12)C1=C(F)C(OC)=CC(OC)=C1F,487.508,115.051888,ng/ml,236.0,Oral multiple dose;,236.00
DDPD15233,Avapritinib,CN1C=C(C=N1)C1=CN2N=CN=C(N3CCN(CC3)C3=NC=C(C=N3)[C@@](C)(N)C3=CC=C(F)C=C3)C2=C1,498.57,813.0,ng/ml,813.0,"PO, oral;",1630.66
DDPD15444,Elexacaftor,C[C@@H]1CN(C2=NC(=CC=C2C(=O)NS(=O)(=O)C2=CN(C)N=C2C)N2C=CC(OCC(C)(C)C(F)(F)F)=N2)C(C)(C)C1,597.66,8700.0,ng/ml,8.7,Oral multiple dose;,14556.77
DDPD15465,Benzhydrocodone,[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CC=C2OC(=O)C1=CC=CC=C1,403.478,19.18,ng/ml,19.18,Oral single dose; Active metabolite;,47.54
DDPD15566,Prednisolone acetate,[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@]([H])(O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,402.4807,321.1,ng/hr,321.1,Liquid;,797.80
DDPD15617,Ferric derisomaltose,[Fe+3].OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O,562.297,408000.0,ng/ml,408.0,Oral single dose;,725595.19
DDPD15685,Selpercatinib,COC1=NC=C(CN2C3CC2CN(C3)C2=CC=C(C=N2)C2=CC(OCC(C)(C)O)=CN3N=CC(C#N)=C23)C=C1,525.613,2980.0,null,2980.0,tumor;,5669.57
